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INTRODUCTION
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INTRODUCTION
Siddha System of Medicine is one of the ancient systems practiced in South
India especially in Tamilnadu, and this system is contemporaneous with those of the
Egyptian, Mesopotamian, Chinese and Grecian medicines. The aim of Siddha
medicine is to make the body perfect, imperishable and to promote longevity.
The unique nature of this system has its continuous service to humanity for
more than 5000 years in combating diseases and in maintaining its physical, mental
and moral health. [1]
The word ‘Siddha’ has its origin in the Tamil word Siddhi which means "an
object to be attained" or "Perfection" or "Heavenly Bliss". [2]
Traditional Siddha medicine upholds balancing, up righting and eliminating
the pathogens as the main principles of treating diseases and maintaining health.
Siddha Medicine gives equal importance in prevention and curing. [3]
Siddha system is mainly based on ‘Andapinda Thathuvam’ that means the
relationship between the universe and human body.  These two are interlinked
through the five basic principles which are known as ‘Panchaboothas’.  The structural
aspect of the human body is said to be ‘Udal Thathus' (i.e. the physical component of
the human body) and the functional units of the human body is said to be ‘Uyir
Thathus’ (the physiological units i.e., Vatham, Pitham, and Kapham).  Functional co-
operation of these two are essential for the maintenance of health. [4]
Yugi Muni describes 20 types of Meganoigal, Madhumegam is one among
them.
The word Madhumegam is very similar and closely resembles with the
chronic metabolic disorder called Diabetes Mellitus-Type II in Modern medicine.
Susruta, known as the Father of Indian Medicine, described many of the
symptoms of Diabetes in his ‘Samhita’ and called the affliction "Madhumegam"
based on the sweetness of the urine passed by those afflicted by this ailment.[5]
Ebers papyrus may be the first recorded evidence about Diabetes, it seems to
be more of historical importance as it was only discovered in the last century. [6]
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Madhumegam is a group of metabolic disorder in which a person has high
blood sugar, either because the pancreas does not produce enough Insulin, or because
cells do not respond to the Insulin that is produced. This high blood sugar produces
the classical symptoms of Polyuria (frequent urination), Polydipsia (increased thirst)
and Polyphagia (increased hunger). [7]
WHO recently compiled data show that approximately 150 million people
have Diabetes Mellitus worldwide and that this number may well double by the year
2025. Much of this increase will occur in developing countries and will be due to
Population growth, Ageing, Unhealthy diets, Obesity and Sedentary lifestyles. By
2020, India is expected to be the Diabetes capital of the world. [8]
Most studies report worse quality of life for people with Diabetes compared
to the general population, especially regarding physical functioning and well-being.
Unfavourable modification of lifestyle and dietary habits that are associated
with urbanisation are believed to be the most important factors for the development of
diabetes. The prevalence of diabetes is approximately twice in urban areas than in
rural population. [9]
Siddha medicine is an answer to all obstinate diseases and chronic sufferers,
especially for treatment of Diabetes Mellitus-Type II. Instead depending totally upon
modern medicines, one can try natural treatment like Siddha medicine for management
of Diabetes Mellitus. Such natural medicines also strengthen the Pancreas and regulate
smooth flow of Insulin.
Siddha is an effective natural treatment modality for Diabetes management.
The Herbal remedies of Siddha helps to reduce blood sugar level down and enhance
glucose tolerance. There are many Siddha medicines that can be used for the
treatment of Diabetes Mellitus Type II and “Pungampoo Chooranam” is one of the
Siddha medicines which have the proven results to reduce the blood Sugar level.
On the whole as a compound drug ‘Pungampoo Chooranam’ will be an
effective as well as Biosafe drug in the treatment of ‘Madhumegam’.
AIM
AND
OBJECTIVES
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AIM:
The Aim of this study is to evaluate the Clinical Efficacy and Safety of Siddha
Medicine “Pungampoo chooranam’’ in the management of Madhumegam.
OBJECTIVES:
1. To review the Siddha literary evidences dealing with Aetiology,
Classifications, Signs & Symptoms, Diagnosis, Diet and Prognosis of
Madhumegam in Siddha system of Medicine.
2. To study Madhumegam in various literatures in comparison with Diabetes
Mellitus -Type II.
3. To understand the incidence of the disease with reference to Age, Sex,
Thinaigal, Paruvakalam, Socio Economic conditions, Diet and Family
history.
4. To explore the unique diagnostic methods mentioned by Siddhars such as
Envagaithervu, Mukkuttram, Udal thathukkal with specific reference by
Naadi, Neerkuri and Neikuri.
5. To implement Siddha and utilize Modern parameters to diagnose and to
confirm the severity & progress of the disease.
6. To evaluate the Bio-chemical analysis of the trial drug.
7. To assess the Acute and Sub- Acute toxicity of the trial drug.
8. To study the Anti Diabetic activity of the trial drug.
9. To evaluate the Clinical study of the trial drug.
10. To analyze the Biostatic analysis of the trial drug.
REVIEW OF
LITERATURE
SIDDHA ASPECTS
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REVIEW OF LITERATURE
SIDDHA ASPECTS
“j¡f jhuâ khål¤njh®fŸ nfŸ
g¡fkhry« g¤ÂUtifÍnk
e¡f ehaf‹ eha»¡nf brhš
ä¡f eªÂ és«Ã éÂ¤jnj”
- njiua® thfl« [10]
According to Therayar Vagadam, “The universe consist of two essential
entities that is, matter and energy which Siddhar’s referred to as Shiva and Sakthi”.
Shiva explained Megarogam to Sakthi. Here Nandhi explains its symptoms to the
world for the benefit of the human kind. This clearly indicates that the existence of
this disease is as old as human race.
“Mk¥gh kåj® brŒj f‹k¤jhny
mufuh nkfbk‹w uhrhthny”
- mf¤Âa® [11]
According to Siddhars, the imbalance of tridosha causes totally 4448 diseases
to human beings. Among them, Megarogam is considered to be the emperor of
diseases.
“ä»D« FiwæD« nehŒbrŒÍ« ünyh®
të Kjyh v©âa _‹W”
- தி ற [12]
All the diseases are due to alteration of three vital humours and seven physical
constituents.
The factors, which affect this equilibrium of vital humours are,
 Unavu Marupadugal (Altered diet habit)
 Kalamarupadugal (Seasonal variations)
 Thega vanmai (Depending upon immunological status)
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Madhumegam has its description in various literatures like Yugi Vaithya
Chindamani, Agasthiyar Gunavagadam.
Earlier, diseases were classified only according to Mukkutram. Yugi Munivar
classified the diseases according to cause, signs and symptoms, and also explained
about the prognosis, treatment and diet, which is now followed by the modern world.
VERUPEYARGAL (SYNONYMS)
Neerizhivu, Ennipuneer, Vegumoothiram, Thithippuneer, Miguneer. [13]
Neerizhivu – Excess of urination.
Ennipu Neer – The urine is sweet in taste.
IYAL (DEFINITION)
Madhumegam is a clinical condition characterized by frequent passage of
urine more than the normal resulting in deterioration and diminution of the seven
thathus.
“m©ikahao¡ fo¡F Úçw§F
ko¡fo¡F miuehê jåny fhQ«
bt©ikahd joa jå‰wh‹ Ão¡F«
ä¡fhd rl«btS¤J nkåf‹W« ”
- ô» it¤Âa Áªjhkâ [14]
These lines quote frequent micturition, more than the normal with large
quantity resulting in detoriation of gradual dimnision of sevan udal thathukkal.
”Úçid¥ bgU¡fby‹W Úçê éy¡fz§nfŸ
ÚythçÂ ngh‰ F¡» Ú£o¡F Kiu jŸshF«
Úé TlhJ if, fhš Úykh éid neuhF«
ÚŸ brhdhÎuå‹ _¢R Úrkh Ka§f¡fh£L«”
- ேதைரய  மகா காிச [15]
Page | 6
Abdomen distends like sea, slurring of speech, peripheral neuritis, lassitude,
dyspnoea are the symptoms of Madhumegam.
As per Athma Rakshamirrtham, body becomes weak, weight loss, dryness
of skin and tongue, excessive thirst, tiredness, excess sleep indicate the presence of
Megaroham.
NOI VARUM VAZHI-AETIOLOGY
“nkfbkD ÚuêÎ tU« éj¤ij
és«ò»nw‹ K‹brŒj f®kªj‹dhš
jhfKl‹ kJgjh®¤j§fŸ e‹whŒ¤
jh‹òÁ¤j yhYŠÁ‰¿d¤Â‹ k§if
nghfkÂ fç¤jyh Y£odªjh‹
nghjnt äŠRjyhš jæ®nkh® beŒghš
VfkhŒ¥ òÁ¤jyh‰ bfhG¤j ñid
ba‹W K©z YtªÚiu¡ Fo¤jyhny
MirÍl‹ ÁWtGjy§fhŒ j‹id
aÂfkh Í©gjhš fhyªj¥Ãš
nghrd§fŸ  brŒjyhš eilaiy¢rš
nghjnt æU¤jèuh f©éê¤jš
njrbk§F Âçjyh äitfshny
Áuªjå‰N lÂf§ bfh©Llnd u¤j«
nrhînj aÂfkhŒ nkfªnjh‹¿¤
bjhšiy brŒÍ« ÚuêÎ« ÏUgjhnk.”
- சரேப திர ேமகநிவாரணேபாதினி எ நீாிழி ேநா ம வ . [16]
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(i) Diet Habits
“nfhija® fyé nghij
bfhG¤jÛ åiw¢Á nghij
ghJthŒ beŒÍ© ghY«
gçÎl ©Õ uh»š
nrhjgh© LUt ä¡f
R¡»y Ãunk fªjh‹
XJÚ çêÎ nru
c©bld t¿ªJ bfhŸns”
- mf¤Âa® 1200. [17]
“c‰gé¡F« ghšbeŒah èiw¢Á bfhŸsš
cçirahŒ Û‹w‹dh štUé U¤j
k‰gé¡F« gjh®¤j¤jhš kJu t°jhš
kªj§fŸ jidbghÁ¤jš ntfh¥ g©l«
F‰gé¡F§ FSªjt‹d k§if nfhZo
F¿¤j ã¤Âiujé® jy¡»å kªj«
J‰gé¡FŠ rßuªjh‹ äf¥gU¤jš
rŠryªjh‹ ga¥gLjš jç¡F« nehna”
- ô» it¤Âa Áªjhkâ [18]
Excessive intake of food, rich in carbohydrate and fat, red meat, sweet food,
rawfood and sleeplessness induces mathumegam, which was quoted by Agathiyar and
Yugi Munivar.
(ii) Sexual Indulgence:
“f‹å ka¡f¤jhš f©oL nkfnk”
- தி ல [19]
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“»uªÂ¥ ò©âuz nkf¡
Ñrf bad‹Dª J‹ kh®¡f‹
mUªjÂ ba‹D« ghŠrhè a‹idia¡
f©Q‰whnd”
- ேதைரய ம வ பாரத [20]
According to Thirumoolar and Therayar, excessive indulgence in sex causes
Megaroham.
(iii) Obesity:
“j‰Ãé¡FŠ rßuªjh‹ äf¥g U¡fš
ršryªjh‹ ga‹gLjš jç¡F« nehna”
- கி ைவ திய சி தாமணி [21]
Obesity is one of the main cause of Madhumegam.
(iv) Psychosomatic Cause:
“Ïa«gnt MWFs« Ã‹dŠ brŒjš
V‰wkhŒ kh‰wh‹bg© r§f« brŒjš
ga«gnt ghyf®fS¡ bfhë¤J Â‹dš
gHik ry«nghwt êjid jL¤jš
ma«gnt Mya¤Â‰ ry«é£nlh®¡F«
MÂah« ntj¤ij¤ Jhஷி¤ njh®¡F«
Ja«gnt Nçaid tz§fh jh®¡F«
RU¡fhf nkf«tªjJ‰ gé¡Fª jhnd”
- கி ைவ திய சி தாமணி [22]
According to Yugi Vaidya Chinthamani, Megaroham may occur due to not
giving proper respect to Guru, Father, Mother, Vedas and God suriyan.
(v) Hereditary:
“Kiwnf£»‹ x‹gJ Ka‰Áahš tªjJ
Jiw nf£»w fU¥g¤Â‰ Wt§»a nkf§fŸ
ãiw ó¤j bfh§ifahŸ ehaf‹ nkhf¤jhš
kiw ngh‰W§ fU¥g¤Âš tsªªjJ.”
- mf¤Âa® it¤Âa fhéa« [23]
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Thirumoolar have noted in his literatures that Hereditary is one among the
causes of the disease Madhumegam. At present researches have also found that
genetic factors play an important role in Madhumegam.
(vi)  Excess Stimulation of Moolatharam:
“rçahdnkf¤jh yghd thÍ
jh‹ òif¡F nkny¿¡ fghy¢ Nlh«
bgçjhd nkf¤jh y¤Â btªJ
nghk¥gh jirbtªJ u¤j« t‰¿¥
gçth»¤ jr thŒthš kªj« bfh©L
bgUªÔå kygªj« cjhd thÍ
éçth»¤ njfbkšyh«él %uhny
bkŒaêªj njfbk‹w ÂUgjh¢nr”
- ேநா நாட [24]
Among the six Atharams, the Moolatharam is situated in between rectum and
genitals, just end of sacral plexus.
In the Madhumegam disease, impaired Abana vayu (excretory junction)
inactivate the moola agini during that time excess intake of food causes inactivation
of dhasavayu which create excessive appetite (Polyphagia) and constipation. Udanan
is also affected. These changes in turn cause the derangement of seven udal
thathukal.
(vii)  Deeds:
“jhnd óUt éÂædhš rhU« Ãâf bsšyh«
khnd®éêahŸ nt£ifædhš tUªJ« Ã‹D« gÁahš
jhnd bghW¤J c©ifædhš jhfªj‹dhš äf¢nrh®ªJ
jhnd fky« ò©zh» brŒÍ« Ãunkf¢ brašjhnd”
- ேதைரய ம வ பாரத [25]
From the above poem, the diseases also occur as a result of bad deeds
committed in previous or this birth.
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MURKURIGUNAM (PREMONITORY SYMPTOMS):
Premonitory symptoms of Madhumegam are polyuria, polyphagia, poly
dipsia. Madhumegam exhibits the following premonitory symptoms from its initial
stage of development itself. The patient experiences voracious hunger, thirst,
perspiration, exhaustion and giddiness. The excessive intake of water to quench thirst
is excreted as excessive quantity of urine (poly uria). In spite of abnormal
consumption of food, stamina continues to decrease.
- NoiNadal [26]
PODHUKURIGUNANGAL (GENERAL SIGNS & SYMPTOMS)
“Twhd nkfkJ ÏUgJ¡F«
Fzªj‹id¢ Át‹brhšy njé nf£f jhwhd
jhfbkhL nrhfnkfª
jçahkš Úçêj  éUkš _¢R
Mwhd mUÁr¤Â Á¤j¥ u«ik
mofo¡fo¡F¤ j©Ùªjh‹m§nf nf£fš
<whd ÏL¥ò¡FŸ fL¥ò fhzš
vY«òH‰w yH‰wy blçÎ lhnk
vçnthL rßubkšyh kiwg£lh‰nghš
vY«ò nehjš ã¤Âiuæš yhik
tçnthL khŒébk¤ jÎ«g¿¤jš
kdJrŠ  ry¥gLjš  fh‰W nt©lš
bkçnthL nkš _¢R äfÎ©lhjš
é¡fbyhL ka¡fªjh‹ bk¤j¡ fhzš
bjçnthL njfbk§F« btSU©lhjš
njfbk¤j thnyhg¥ gLjš fhnz”
- ô» it¤Âa Áªjhkâ [27]
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Common Symptoms:
Thirst Polyuria
Polydipsia Cough
Anorexia Dyspnoea
Delirium Pain in the hip and burning sensation
Sleeplessness loss of weight
Hiccough Flatulence
Anaemia Giddiness
NOI VAGAIKAL - (CLASSIFICATION)
Megarogam is classified into twenty varieties to quote from Agasthiar.
“c£oz nuhf¤jhY«cW«bgU«
gÁædhY§ f£léœ nfhij khj®
fyék£oyh ikayhY K£lwh ehYkhW K«
_‹W bkh‹W bkh‹W Â£lkhŒ
tUtbj‹W ÂUKå aUë¢ brŒjh®”
-mf¤Âa® [28]
Yugi Munivar classifies the same as
“trå¤j nkfkJ æu©L g¤J
thj¤Â‰ Ãwªjry« ehnyahF«
Ãrå¤j Ã¤j¤ÂY  ‰wgé¤j
nguhir yªjhD khW khF«
njråªj nr£Lk¤ÂY‰g é¤j
Óuhd ryªjhD« g¤njahF«”
- ô» it¤Âa Áªjhkâ [29]
According to Theraiyar
“fêÍ« thj« eh‹fhY« fhÍ« Ã¤j khwhY«
RêÍ« nr¤Jk© g¤jhY« brhšY« ehyŠrhŒ njh‹W«
- njiua® thfl« [30]
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NOI VAGAIGAL:
BOOKS NOI ENN VALI AZHAL IYAM
ô»it¤ÂaÁªjhkâ 20 4 6 10
mf¤Âa® 1200 20 4 6 10
njiua® thfl« 20 4 6 10
j‹tªÂç it¤Âa‹ 20 4 6 10
rungªÂu ÚçêÎ nuhf Á»¢ir 20 4 6 10
The above books describe twenty different kinds of megam (urinary disorders)
on the basis of colour, consistency, taste, smell, weight etc.
Out of these twenty different kinds four varieties are caused by Vali, six varieties
are caused by Azhal, ten varieties are caused by Iyam.
Madhumegam comes under the classification of Azhal.
CLASSIFICATION OF MEGAM:
According to Yugi Vaidhya Chinthamani,
 Vaadha Neer Vagaigal:
“jç¤Â£l thj¤Â‹ ryªjh dhY
jåahd ehY¡F« ngnu bj‹åš
mç¤Â£l M¢ÁabfªÂ nkf¤njhL
mj‹ÃwF R‰wkh  nkfbk‹W
Ãç¤Â£l Ãuäa nkfbk‹W
nguhd kh§fué nkfbk‹W”
- ô» it¤Âa Áªjhkâ [31]
Vali – 4
1.  Neimananeer
2. Pasumana neer
3. Seezhmana neer
4. Sathaimana neer
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 Pitha Neer Vagaigal:
“Kiwahd Ã¤j ry khWkhF«
KÂ®ªj m¥Ãa bk‹W« Ãuäa bk‹W«
Jiwahd rh«Õ®zkJ«g bk‹W«
rh¤Âfnk ahWéjª j‹ndh lhW”
- ô» it¤Âa Áªjhkâ [32]
Azhal – 6
1. Yanai kozhupu mana neer
2. Katrazhai mana neer
3. Chunna mana neer
4. Innipu megam
5. Palingu neer
6. Muyal kurithi neer
 Iya Neer Vagaigal
“Mwhd Ány£gry« g¤J j‹id
mu‹ brhšy M¤jhŸ jh‹ nf£F« nghJ
thwhd trhnkf« c¤rnkf«
k¢Áahnk f¤njhg Ñj nkf« öwhd Ruhç R¡y K¤j
nkf« R‰wkh«Ã  dhåbahl tyz nkf©
nfwhd bjÍ¤jakh nkf bk‹W
br¥Ãdh® Ány£ g¤Â‹ brY¤J¤ jhnd”
- ô» it¤Âa Áªjhkâ [33]
Iyam – 10
1. Iaya Neer
2. Thuimai Neer
3. Moolai neer
4. Ilaneer
5. Kal  neer
6. Thavala Neer
7. Kazhu neer
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8. Then neer
9. Uppu neer
10. Kavichi Neer
Yugi described four types under the Vatha premeham, six types under the pitha
prameham and ten types under Kaba prameham.
NOIKURI KUNANGAL – (CLINICAL FEATURES)
Polyuria, Polyphagia, polydipsia, perspiration, exhaustion, insomnia, giddiness
and loss of weight are seen even at normal consumption of food.
COMMON SIGN AND SYMPTOMS OF PITHA PRAMEHAM:
“m¿ant Ã¤jry khW¡Fªjh‹
m§fkÂ‰ brŒ»‹w Fz¤ij¡ nfshŒ
j¿ant rßu« t‰¿ baçÎ§lhF«
rl¤ÂYª ÚçYªjh‹ fé¢R©lhF«.
bj¿ant Ó¥nghY§ f‰whiH nghY«
nrš nghYª nj‹ nghY« eh‰w K©lh«
bt¿ant Õr¤Â‰ nfhr¤Â‰ Fj¤Âš
äFÛuš ehÃæY« nt¡fh lhnk
nt¡fhlhŒ éuz K©lhŒ thŒjh‹ ehW«
é¡fbyhLmUÁaha¢ RuK©lhF«
Ô¡fhlhŒ¤ njfªjh‹ »ilbfh£lhJ
Âa¡fbkhL_®¢irÍ©lh ka¡f khF«
rh¡fhlhŒ  ehtwª j©Ùª jhf«
r¡ÂbahL  rßubkšyhª js®¢Á ahF«
jh¡flh kyrŠryªjh‹ äfÎ©lhF«
rkFzªjh‹ Ã¤j ry khW kh¢nr”
- ô» it¤Âa Áªjhkâ [34]
As per the above poem, polyuria, polyphagia, Polydipsia, fever, angular stomatitis,
burning sensation all over the body, loss of weight, are common signs and symptoms
of pitha prameham.
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MUKKUTRA IYAL:
“வாதமா  பைட த  பி த வ னியா  கா
ேச ம  சீதமா ைட ”
- ேதைரய ம வ பாரத [35]
 Vali:
Sites of Vadha:
Below Naval, Urinary bladder, intestines, Pelvis, umbilical cord, thigh, bone,
skin, nerve endings, joints, Musculature, hair root.
Properties:
Dryness, Lightness, Clearness, Coolness, Mobile, Formless.
Function:
 Praanan (Uyirkaal) :
This controls knowledge, mind and five sense organs, which are useful
for breathing and digestion.
 Abaanan (Keezh nokku kaal) :
This is responsible for all down ward movements such as passing urine,
stools,  semen, menstrual flow etc
 Samaanan (Nadukkaal) :
This aids in proper digestion.
 Viyaanan (paravukaal):
This is responsible for all movements of all parts of the body.
 Uthaanan (Mel Nokkukaal) :
Responsible  for  all  upward  visceral  movements,  such  as  vomiting,
eructation  and nausea.
 Naagan :
Responsible for opening and closing the eyes.
 Koorman :
Responsible for vision and yawning.
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 Kirukaran :
Responsible for salivation, nasal secretion and appetite.
 ` Devathatthan :
Responsible for Laziness, sleeping and anger.
 Thananjeyan :
Produces bloating of the body after death. It escapes on the third
day after death bursting out of the cranium.
In Madhumegam
 Piranan : Normal
 Abanan : Constipation, Noctural polyuria, frequency of
micturation.
 Viyanan : Symmetrical sensory disturbances, peripheral neuritis,
pain all over the body, Burning sensation in the sole of
foot and palm, Skin infection and carbuncle.
 Udanan : Normal
 Samanan : Poly Phagia
 Nagan : Normal
 Koorman : Diabeic Retinopathy, Cataract
 Kirukaran : Poly Phagia
 Devathathan: Normal
 Thananjeyan: -
 Azhal:
Sites of Pitha:
Between the heart and the naval, sweat, lymph, blood, stomach, urinary
bladder, heart, saliva, eyes and skin.
Properties:
Dry, cold, hot, light, subtle, keen, soft, liquid, bitter.
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Function
1. Anal Pittham : It promotes appetite and helps in digestion.
2. Ranjagam : It gives colour to the blood.
3. Praasagam : It gives complexion to the skin.
4. Aalosagam : It brightens the eyes.
5. Saathagam : It controls the whole body.  It has the property to
fulfil all the activities which the mind desires.
In Madhu megam
Anala Pitham - Excess hunger
Ranjaga pitham - Pallor sometimes
Alosagapitham - Dimness of vision
Saathaga pitham - Lassitude
Prasaga pitham - Dry skin
 Iyam:
Sites of Kapha:
Above the heart, stomach, fat, sperm, tongue, uvula, bone marrow, blood,
nose, nerves, bones, large intestine, eyes, joints.
Properties:
Heavy, cold, mild, watery, sweet and stable.
Function:
 Avalambagam : Lies in the lungs, controls the heart and other
kabhams.
 Kilethagam : Lies in the stomach, makes the food moist, soft
and helps in digestion.
 Pothagam : Responsible for identifying taste.
 Tharpagam : Present in the head and responsible for the
coolness of eyes.
 Santhigam : Responsible for lubrication and free movements
of joints.
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In Madhumegam
Avalambagam - Normal
Tharpagam - Burning sensation in the eyes
Santhigam - Joint pain
Kilethagam - Excessive appetite
Pothagam - Normal
SEVEN UDAL THATHUKKAL (PHYSICAL CONSTITUENTS)
Annamaya kosa is constituted by seven Thathus. They are the basic tissues of
our body.
Normal functions:
 Saram:
It is responsible for the growth and development. It keeps the individual in good
spirit and it nourishes the blood.
 Senneer:
Blood imparts colour to the body and nourishes the muscle responsible for the
ability, intellect of the individual.
 Oon:
It gives shape to the body according to the requirements for the physical activity,
nourishes fat.
 Kozhuppu:
It helps in lubricating the different organs and maintains only matter of the body.
 Enbu:
Supports the system and responsible for posture and movements of the body.
 Moolai:
It fills the bony cavity, nourishes semen, imparts strength endurance and shining
appearance.
 Sukkilam / Suronitham:
It is responsible for reproduction. In healthy people, they function in a harmony,
while in diseased people, they are deranged.
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In Madhumegam:
Saaram : Tiredness, General weakness
Senneer : Pallor
Oon : Emaciation
Kozhuppu : Dry skin
Enbu : Later stage due to infection it affects
the bone and sometimes leads to
amputation.
Moolai : Affected in Chronic stage.
Sukkilam / Suronitham  : Impotence, Sexual urge is reduced.
So, in Madhumegam, Seven Udal Thathukkal are deranged.
MUKKUTRA VERUPADUGAL (PATHOGENISIS):
The disease Megaroham, due to external (or) internal causes affects balance in
the ratio of vali, Azhal, Iyam. This imbalance affects the Keelnokkukal, which inturn
affect the seven udal thathukkal. Saram gets affected and there is loss of appetite.
Seeneer also get affected with the net result even if the patient eats more nourished
food (polyphagia) there won’t be any improvement in health.
An imbalance in pitham does imply an imbalance in other two kutrams too and
causes derangement of dasa vayu and seven udal thathukkal which cause the disease
and other complications.
PINIARI MURAIMAI- (DIAGNOSIS):
Diagnostic methods in Siddha system are very unique and solely based on
clinical acumen of the physician.
 Poriyal Arithal (or) understanding by the five organs of perception (Mei, Vai,
Kann, Mooku, Sevi).
 Pulanal Arithal (or) understanding by the sense objects (Uraithal, Suvaithal,
Parthal, Mugarthal and Kettal).
 Vinadal (or) Interrogation.
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Tools used by Siddha Physicians:
 Kanndal (Perception)
 Karuthal (Inference)
 Urai (The instruction of the inspired)
The application of these three is very extensive in diagnosis and treatment.
ENN VAGAI THERVU (EIGHT TOOLS OF DIAGNOSIS)
 Naa:
Colour of the tongue, size, shape, anomalies, surface, mobility and local lesion
should be noted. Coating deposition of the tongue, increased salivation and dryness of
the tongue.
In Madhumegam, the tongue remains dry and at times black.
 Niram:
Colour of the skin all over the body, a local region of affection, conjunctiva,
tongue, nail bud and hair etc.
Vatha Udal - Black and Whitish colour
Pitha Udal - Yellow or Reddish colour
Kabha Udal - White or Golden colour
Thontha Udal - Mix of two udal colours.
In Madhumegam, the colour of skin is different from original complexion,
discoloured.
 Mozhi:
Observation of speech and voice.
In uncontrolled Madhumegam which leads to cerebrovascular disorder,
speech disorder sets in.
 Vizhi:
Colour, character, vision should be observed.
In uncontrolled Madhumegam cataract set in last. In longstanding cases, the
Madhumegam affects retina and causes diabetic retinopathy which is the major
cause of blindness.
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 Sparisam:
Colour of the skin (Vali, Azhal, Iyya udal), Eruption, Hemorrhages, Ulcers, Boils,
trophic changes in the skin can be identified.
Any changes in the internal organs can be noted by palpation (or) percussion.
In  Madhumegam,  increased  tendency  for  fungal  infection  like moniliasis  and
vulvities.
In Madhumegam the skin is dry and pale.
 Malam:
Quantity, colour, smell, froth should be observed.
In Madhumegam, constipation sometimes yellowish loose stool are passed.
 Muthiram:
Quantity colour froth smell and specific gravity of urine should be noted.
 Urine:
Colour: In Madhumegam it is clear and white.
Specific Gravity: In Madhumegam, urine is thick in consistency like honey.
Smell: Honey like smell
Froths: In Madhumegam the urine is frothy at the time of urination.
Deposits: In Madhumegam few epithelial cells are present in urine.
Normal quantity of adult urine is 750 – 2500 ml in 24 hours.
Disturbing Polyuria at night (nocturia ) and Glucosuria ( the presence of sugar in
urine) are present.
NEER NIRAKKURI:
“mUªJ kh¿ujK«ménuhjkjhŒ
m~fš myjš mfhyñ‹ jé®ªjH‰
F‰wstUªÂ cw§» itfiw
Mo¡fyr¤ jhéna fhJ bgŒ
bjhUKT®¤j¡ fiy¡F£gL Úç‹
ãw¡F¿ beŒ¡F¿ ãUä¤jš flnd.”
- ேநா  நாட [36]
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Collection of Sample Urine:
The patient must take well cooked food in the previous day. The intake must
be proportionate to the degree of his appetite. Food intake should be taken, at
appropriate time. The patient must have sound sleep on the previous night. The urine
is collected on the dawn of the next day in a glass container and closed immediately to
prevent contamination. This specimen must be examined with in one and half hours.
This procedure should be followed strictly to get accurate observation of Neerkuri and
Neikuri.
NEIKKURI:
“ãw¡F¿¡ Fiu¤j ãUkhz Úç‰
Áw¡f bt§bzŒnah® ÁWJë eL éL¤
bj‹Dw¤ Âwªjbtë nafh jik¤jÂ
å‹wÂtiy ngh« be¿éêa¿Î«
br‹wJ òfYª brŒÂia Íznu.”
- ேநா நாட [37]
The diagnosis and prognosis of deranged Mukkutrams are studied on the basis
of the behaviour of a drop of gingelly oil gently droped on the surface of the urine
kept in a wide vessel in the sunlight.
“K¤bjh¤J ã‰»‹ bkhHtbj‹ fgnk.
- ேநா நாட [38]
In Madhumegam, the oil dropped in urine is like a pearl and if the oil spreads
slowly, the prognosis of the disease is slow and good.
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NAADI:
Pulse is the confirmatory diagnosis.
In Madhumegam,
“ÏUäna Ã¤jK« thjK«Tooš
kUÎry nkf« thUÂ nghyhF« cUt«
ntwhU K©lÎl‹ fhªÂL«cUfnt
ñndhL c¿ŠÁ Ïå¡Fnk”
- தி ல [39]
Coupling of Azhal and vadha naadi causes excessive urine as vast as sea, loss
of weight and polyphagia .
When kabha merges with vadha ,glucosuria,emaciation ,anaemia develops.
“gh®¤ÂL _‹W« gÂªJ   bkèªJ ã‰»š
nj®ªÂL  nk tª njh‹¿na bghUªÂbkŒæš”
- தி ல நா [40]
When all the three nadi’s, runs in low volume,diabetes develops.
MADHUMEGA GUNAM:
“Ïå¡»‹w  thj¤ Âilnrçš Iaªjh‹
gå¡»‹w fŸS¥ gjånghš ÚnuhL«
få¡»‹w nkå fiuªJ btS¥ngW«
jå¡F« kJnkfª j¥ghJ Iand”
- தி ல [41]
The coupling of the Vali and Iya naadi, causes increase in urination, and
diabetes develops.
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AVATHAIGAL :
If the disease is not controlled or left untreated, the below complications
follow gradually.
mt¤ij – 1
“fhznt Kjty¤ij¢  rßuª jhD«
fdkhf¥ gU¤ÂW» Ú®¤J thu«
ntznt bt©lh¡»a fy« g©Q«”
- சி த ம வ
Obesity sets in.
There is obstruction in urinary flow.
Urinary passage expands due to inflammation.
mt¤ij – 2
“ ä¡f Ïu©lhkt¤ij és«g¡nfshŒ
_znt_¤Âu¥ ÕilÍkh¢ R¡»y
KfkG»¤ nj#Rjh‹ äfnt F‹W«.”
- சி த ம வ
Bad odour while Micturation.
Loss of complexion in face and body.
mt¤ij – 3
“ehznt  _‹whF kt¤ij¡ Fªjh‹
ehtwS« thÍtJ ÛWªjhnd”
- சி த ம வ
Tongue generally becomes dry.
Abdomen is distended due to flatulence.
mt¤ij – 4
“jhdhd ehyt¤ij a§f jhf«
r‹åaJ ghj K©lh«”
- சி த ம வ
Severe thirst occurs.
Causes Delirium.
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mt¤ij – 5
“IªJ t¤ij¤
njwhd Ú®bgUfª jhJ eZl«”
- சி த ம வ
Quantity of urine increased.
Loss of semen (impotence).
mt¤ij – 6
“ ãiy ahwh kt¤ijÍl‰ »il bfhŸshJ
_dhd _®¢ir tU«”
- சி த ம வ
Sleeplessness is present.
Difficulty in breathing is experienced.
mt¤ij - 7
“VGt¤ij
ä¡ftnuh ÁfŠRthrª njf rh£a«”
- சி த ம வ
Tongue becomes tasteless.
Difficulty in breathing is experienced.
Loss of Appetite.
General weakness persists.
mt¤ij – 8
“Vdhd v£lht jt¤ij jhnd
vG»uªÂ ÃsitÍªjh‹ äfÎ©lhnk”
- சி த ம வ
Abscess is formed.
Presence of Carbuncle
mt¤ij – 9
“c©lhF bkh‹gjh kt¤ij nfshŒ
xG¡fhd Mrhu§ »Uä Í©lh«”
- சி த ம வ
Irregularities in daily habits like bowel habits.
Recurrent Infection occurs.
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mt¤ij – 10
“g©lhd g¤jhªj it¤ij¡ nfshŒ
ghukh«  ra§f©L gu¤J¡nfF«”
- சி த ம வ
Secondary infection like Tuberculosis may sets in due to loss of
immunity.
Other complications of Madhumegam:
Meganeer Kattigal (Diabetic Carbuncle)
1. Madaku Katti
2. Ammaiodu Katti
3. Valai Kann Katti
4. Athomuga Katti
5. Paisura Katti
6. Kadalai Katti
7. Kadugu Katti
8. Thirathi Katti
9. Nilapoosani Katti
10. Megavithirathi Katti
PROGNOSIS (ÔU« Ôuhjit):
“brŒant t¢rukhª j©l khd
brakhd KJFj©il¥ g‰¿ ã‰F«
bgŒant bgUeu«Ãš nkfªjhD«
Ãw¡Fbk‹nw jhd¿ ªJ thjªj‹dhš
ÃŒant Ãwªjfy  khwh yrh¤Âa«
Ã¤j¤Â‰ Ãwªjry khW« ah¥a«
igant  nr£Lk¤Â‰ Ãwªj g¤J«
gukDiu¤ jh® rh¤a« guhgç¡nf”
- கி ைவ திய சி தாமணி [42]
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“têÍ« thj« eh‹fhnk  khwh jéœjª j‹dhny
bghêÍ« thj« ãšyhJ nghnk  kUªij¥ bghŒbadnt”
- ேதைரய வாகட [43]
The four types of Megam caused as a result of imbalance of Vali are incurable.
The six types of Megam arising with disparity of Azhal could be cured with great
difficulty.
But ten types of megam arising due to Iyyam are curable.
vªbjªj nuhf§fëš ÁWÚ®mÂfç¤jhY«FiwªjhY« ÔJ
“bt¥ò  Ãâajåš bt«nkf¤jhš tUªÂ‹
j¥ò äif Únu jhåw§»‹ - br¥ò«
»uhâæ‰ gh©oš Fs®Ú® RU§»‰
Ãuhz‹ ÃçÍbkd¥ ngR”
- க சாமிய [44]
Very excess of urination in Megaroham causes death.
“JÂ¥ghd nkf¤Âš ÚçêÎ khfh
njh‹¿a  ÚçêÎ j©Ù® thjKkhfh”
-சதக நா [45]
If Megaroham is associated with excessive urination, it is difficult to cure. If
Megaroham coexist with vali it is incurable.
“nkf¤Âš ÚçêÎ nkÎkÂš thj nehŒ
ntf tæ¤JŸ tæ‰WisÎ - nrhf é¡fš g‹D é¡»š
j‹åš gfçis¥ò¥  gh§f jå‰
Ã‹dis ahfhJ ngR”
- ேநா நாட . [46]
In Megaroham complications associated with carbuncle, Morbid thirst,
excessive body heat, shock and sweat occurs and the prognosis will be bad.
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“nt®itjå‰ fgK« nkÎkÂš é¡fš nehŒ
fh®K»š ne® TªjyhŒ f©L nkš - Ó®bfhŸ
kU¤Jt¤Â‰nw®ªj kÂÍilahuhé
jç¤Âuh bj‹g®rç”
- ேநா நாட [47]
If Iya megam is associated with sweat hiccough, the prognosis is bad.
nkf« ÏUgJ¡F« g¤Âa«:
“nkf äUgJ¡F g¤Â  aªjh‹
gh§fhf Îiu¤Âlnt gRé‹ bt©bzŒ
bghçthf vUik nkh® bgh‹dh§fhâ
ng®bg‰w ÁWÑiu KR£il ahF«
Mçthf mtiubahL òlš KU§if
mÂrukh§  f©L  rU¡  fiuÍ  khF«
kçthf khjisah« ngß¤ jhF«
kfhés« gHKªÂç¥ gHK khnk
Mnkng a‹ thiH¥ gHK§ f¢rš
m¤Âæl¥ ÃŠRÁW gaWgHŠ nrhW
ghnkgHŠ nrh‰WÚ® btªjaŠ Óufkh«
ghfš Õç¡ f§fhŒfU nt¥Ãiy bfh¤jkè
nenkbe‰ bgh¿ vŸS KRKR¡if ahF«
neuhd ešby©bzŒ ò©z¡FSªJ
jhnkf äUgJ¡F« g¤a t®¡f«
rh‰¿dh® Át‹whDª jhŒ¡F¤ jhnd”
- ô» it¤Âa Áªjhkâ [48]
The following foods are preferred for Madhumegam:
bgh‹dh§f©â, ÁWÑiu, bfh¤jkšè, fUnt¥Ãiy,
KRKR¡if, ghfš, Õ®¡F, mtiu, KU§if, btªja«, Óuf«, vŸ, gRé‹
bt©bzŒ, vUik nkh®, btªja«, ÁWgæW, cSªJ Ïit nkf«
ÏUgJ¡F« g¤Âa« MF«.
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MARUTHUVAM:
The treatment in Siddha Medicine is aimed at keeping the three kutrams (Vali,
Azhal and Iyam) in equilibrium and maintenance of the seven udal thathukal.
In Siddha science, the treatment is not only for removal of the disease, but for
the prevention and improving the body condition after the removal of the disease.
This is classified as Kappu (Prevention), Neekam (Treatment) and Niraivu
(Restoration)
 Kappu:
Prevention is better than cure is a proverb.
Siddha principles based mainly on prevention as mentioned in “Theraiyar pini
Annuga vithi” by Theraiyar. The aim of the treatment is to bring the affected
thathus and Mukkutram to normal levels by eyamma, niyamma, diet and medicine.
 Neekam:
For the disease Madhumegam, PUNGAMPOO CHOORNAM - 2gm twice a day is
given.
 Niraivu:
Physical, Psychological, social and economic rehabilitation of individual is known
as Niraivu.
In Madhumegam, Azhal kutram and other two kutrams Vali and Iyam deranged
and causes impairment of dasavayu which in turn affect the seven udal thathukkal.
PHYSICAL EXERCISES
“e©ò bgw Î©l Ã‹ò FWeilÍ§ bfhŸnth«”
- gjh®¤j Fz Áªjhkâ [ 49]
The need for walking is emphasized by Therayar. Exercise forms an important
component along with drugs and diet management of Diabetes Mellitus – Type II.
Patients should be encouraged to take regular physical activity in form of walking,
gardening, swimming and cycling for 30 minutes daily to improve insulin sensitivity
and lipid profile and lower blood pressure.
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YOGA FOR MADHUMEGAM
YOGA:
Yogic Physical exercise makes the muscles healthy and strong. It also tones up
all the involuntary organs which are concerned digestion, evacuation, circulation,
respiration and secretion and through them, the autonomic nervous system which
regulates their activities.
- Yoga Aganas for Health & Vigour [50]
Yoga is primarily the process of self culture. Yoga according to
Thirumandiram is the attainment of spiritual, psychological and physical perfection.
“உட பா லழியி உயிராலழிவ
திட பட ெம ஞான ேசர மா டா
உட ைபவள உபாய அறி ேத
உட ைபவள ேத உயி வள ேதேன”
- தி ல [51]
As a body is said to be divine, Thirumoolar advised that each and every
individual aspiring for self realisation should practice yoga. It is a science that helps
to lead a pure and healthy life, the practice of yoga prevents the decay of tissues by
increasing with abundant energy force.
“இயம நியம எ னிலாஆதன
நய பிரணாயாம பிர தியாகார
சய தாரைன தியான சமாதி
அய அ டா க மாவ மாேம”
- தி ல [52]
Asanas are nothing but a kind of yoga. There are innumerable types asanaas
described in Siddha text.  Each and every yogasana is indicated for a definite effect in
a particular region of the body by stimulating the internal organs to function in a
normal way.
Page | 31
The following Asanaas will help to manage madhumegam:
1. Mayurasanam
2. Dhanurasanam
3. Paschimottanasanam
4. Pawanamukthasanam
5. Ardha Matsyendrasanam
1. Mayurasanam:
Mayur means peacock. In this asanam the legs are stretched like the wings of
the peocock and so get the name Mayurasanam. The palms on the floor, and put
pressure on both sides of the elbow with the stomach, the whole body without
touching the ground, like an elevated position that is called mayurasanam. Given
below is a step by step procedure to perform and benefits of this asanam.
Practice:
 First kneel down on the floor, then make sure that there is some space
between the legs.
 Now join the hands and keep the palms in between the gap of the legs.
 Then bend a little and keep the abdomen on the elbow of the hands.
 Stretch the legs one by one slowly and straighten the elbows.
 The toes alone should be on the ground.
 Looking at this now the head to legs the body should be on a straight line.
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 After being at the same stage we have to be there for some time and then
release the breath slowly and hold all your weight on the elbow. Now bend
your head little towards front and rise your legs a little slanting.
 Be at the same position for 20 to 30 seconds. Then slowly kneel down your
legs and release the hands.
Benefits:
It induces the pancreas and helps in preventing diabetes.
2. Dhanurasanam:
Dhanurasanam has been named after the shape the body takes while
performing it - that of a bow. Dhanu means bow.
Practice:
1. Lie on your stomach with your feet hip-width apart and your arms by the side
of your body.
2. Fold your knees, take your hands backwards and hold your ankles.
3. Breathing in, lift your chest off the ground and pull your legs up and back.
4. Look straight ahead with a smile on your face.
5. Keep the pose stable while paying attention to your breath. Your body is now
curved and taut as a bow.
6. Continue to take long deep breaths as you relax in this pose. But bend only as far
as your body permits you to. Do not overdo the stretch.
7. After 15 -20 seconds, as you exhale, gently bring your legs and chest to the
ground. Release the ankles and relax.
Benefits:
Helps regulate the pancreas and is recommended for people with diabetes.
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3. Paschimottanasanam
“Paschima” means your “back” and “Uttana” means “stretching“. This
asana covers the stretching of the whole body from head to heels so it is called as
Paschimottanasnam.
Practice:
1. Sit down straight with your legs together by stretching in front of you. keep your
head neck and spine erect.
2. Place the palms on your respective knees.
3. Now bend your head and trunk slowly forward to catch the toes with the thumb,
index and middle fingers without bending knees.
4. Take a deep breath and exhale slowly. Try to touch your head to your both knees
as shown in above image.
5. Bend the arm and try to touch the elbow on the floor.
6. Exhale completely and holding out your breath stay in this posture for a few
seconds.
7. After few seconds slowly return to your starting position.
8. Breathe normally.
9. Repeat this for 3-4 times.
Benefits:
1. It acts as a stress reliever.
2. Reduces fatty deposits in the abdomen.
3. Remove anxiety, anger and irritability.
4. It induces the pancreas and helps in preventing diabetes.
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4. Pawana muktasanam:
Pawana muktasanam knows as Wind Removing Pose. It is beneficial to cure
gas problems and poor digestion. Regular practice of Pawanamuktasanam helps to
stimulate bowel movement which is very necessary for removing waste material.
Practice:
1. Lie flat on your back and keep the legs straight and relax breathe deeply and
rhythmically.
2. Inhale slowly and lift the legs and bend in the knee. Bring upwards to the chest till
your thigh touches to stomach
3. Hug your knees in place and lock your fingers.
4. Try to touch the knee with your nose tip. This is not easy in first time. But regular
practice you can do this. Hold this position for 20 to 30 seconds. You can extend
it till 1 minute as per your capability.
5. Now exhale slowly and come back to the original position that is Shavasana (Lie
straight)
6. This is very beneficial for stomach abs. The results are very impressive.
7. Practice 3 to 5 cycles each day.
Benefits:
1. Cures acidity Indigestion and Constipation.
2. Very good for all abdominal organs.
3. Regular practice cures gastrointestinal problems.
4. It induces the pancreas and helps in preventing diabetes.
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5. Matsyendrasanam:
Ardha means Half, Matsyendra means King of fish.
Practice:
 Sit with the legs straight and relax the whole body.
 Place the sole of the right foot flat on the floor on the outside of the left knee.
 Bend the left leg and lay the left heel beside the right buttock. Both buttocks
remain on the floor. The back is upright and relaxed.
 Bring the left arm to the outside of the right knee and grasp the right ankle.
 Turn the upper body as far as possible to the right, place the right arm across
the back and look over the right shoulder. Breathing normally remains for a
few minutes in this position and relax the whole body.
 Slowly return to the starting position.
Benefits:
Promotes mobility of the spine and hips. The twist aids release of tension from
the deep layers of muscle in the back. The breath is also deepened in this position.
Function of the kidneys and pancreas is stimulated and the ability to concentrate is
improved. [53]
MODERN ASPECTS
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MODERN ASPECTS
DEFINITION
Diabetes Mellitus is a group of metabolic disorder characterized by
Hyperglycaemia resulting from defects in Insulin secretion, Insulin action, or both.
The chronic Hyperglycaemia of Diabetes is associated with long-term damage,
dysfunction, and failure of different organs, especially the eyes, kidneys, nerves,
heart, and blood vessels.
Several pathogenic processes are involved in the development of Diabetes.
These range from autoimmune destruction of the β-cells of the Pancreas with
consequent Insulin deficiency to abnormalities that result in resistance to Insulin
action. The basis of the abnormalities in carbohydrate, Fat, and Proteins metabolism
in Diabetes is deficient action of Insulin on target tissues. Deficient Insulin action
results from inadequate Insulin secretion and/or diminished tissue responses to Insulin
at one or more points in the complex pathways of hormone action. Impairment of
Insulin secretion and defects in Insulin action frequently coexist in the same patient,
and it is often unclear which abnormality, if either alone, is the primary cause of the
Hyperglycaemia. [54]
EPIDEMIOLOGY:
The application of Epidemiology to the study of Diabetes Mellitus has
provided valuable information on several aspects of this disease such as its natural
history, prevalence, incidence, morbidity and mortality in diverse populations around
the world. Identification of the cause of the disease and the possible preventive
measures that could be instituted to arrest or delay the onset of this disease which has
reached epidemic proportions in both the developed and the developing nations.
Unfortunately, the improvement in outcomes for individual patients with Diabetes has
not resulted in similar improvements from the public health perspective. [55]
Diabetes is fast gaining the status of a potential Epidemic in India with more
than 62 million Diabetic individuals currently diagnosed with the disease. In 2000,
India (31.7 million) topped the world with the highest number of people with Diabetes
Mellitus followed by China (20.8 million) and United States (17.7 million). The
prevalence of Diabetes is predicted to double globally from 171 million in 2000 to
366 million in 2030 with a maximum increase in India. It is predicted that, by 2030
Diabetes Mellitus may afflict up to 79.4 million individuals in India, while China
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(42.3 million) and the United States (30.3 million) will also see significant increase in
those affected by the disorder. [56]
India currently faces an uncertain future in relation to the potential burden that
Diabetes may impose upon the country. Many influences affect the prevalence of
disease throughout a country, and identification of those factors is necessary to
facilitate change when facing health challenges. [57]
ETIOLOGY:
Type I Diabetes occurs when your immune system, the body’s system for
fighting infection, attacks and destroys the Insulin-producing beta cells of
the Pancreas. Type I Diabetes is caused by genes and environmental factors, such as
viruses, that might trigger the disorder.
Type II Diabetes is the most common form of Diabetes and it is caused by
several factors, including lifestyle factors and genes.
Gestational Diabetes is a type of Diabetes that develops during pregnancy, and
is caused by the hormonal changes of pregnancy along with genetic and lifestyle
factors. [58]
OTHER CAUSES:
 GENETIC MUTATIONS:
 Monogenic Diabetes is caused by mutations, or changes, in a single gene.
These changes are usually passed through families, but sometimes the gene
mutation happens on its own. Most of these gene mutations cause Diabetes by
making the Pancreas less able to make Insulin. The most common types of
monogenic Diabetes are Neonatal Diabetes and Maturity-Onset Diabetes of
the Young (MODY). Neonatal Diabetes occurs in the first 6 months of life.
 Cystic Fibrosis produces thick mucus that causes scarring in the Pancreas.
This scarring can prevent the Pancreas from making enough Insulin.
 Hemochromatosis causes the body to store too much iron. If the disease is not
treated, iron can build up in and damage the Pancreas and other organs.
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 HORMONAL DISEASES:
Some hormonal diseases cause the body to produce too much of certain hormones,
which sometimes cause Insulin resistance and Diabetes.
 Cushing’s syndrome occurs when the body produces too much Cortisol and
often called the “Stress hormone.”
 Acromegaly occurs when the body produces too much growth hormone.
 Hyperthyroidism occurs when the thyroid gland produces too much thyroid
hormone.
 DAMAGE OR REMOVAL OF THE PANCREAS:
Pancreatitis, pancreatic cancer, and trauma can all harm the beta cells or make
them less able to produce Insulin, resulting in Diabetes. If the damaged Pancreas is
removed, Diabetes will occur due to the loss of the beta cells. [59]
PATHOPHYSIOLOGY:
There is a direct link between Hyperglycaemia and physiological and
behavioural responses. Whenever there is Hyperglycaemia, the brain recognizes it and
sends a message through nerve impulses to Pancreas and other organs to decrease its
effect.
 TYPE I DIABETES MELLITUS:
Type I Diabetes is characterized by autoimmune destruction of Insulin
producing cells in the Pancreas by CD4+ and CD8+ T cells and macrophages
infiltrating the Islets. Several features characterize Type I Diabetes Mellitus as an
autoimmune disease.
1. Presence of immuno-competent and accessory cells in infiltrated
Pancreatic Islets.
2. Association of susceptibility to disease with the class II (immune
response) genes of the major histocompatibility complex (MHC;
Human Leucocyte Antigens HLA).
3. Presence of Islet cell specific autoantibodies.
4. Alterations of T cell mediated immune regulation, particularly in CD4+
T cell compartment.
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5. The involvement of monokines and TH1 cells produce inginterleukins
in the disease process.
6. Response to immunotherapy and
7. Frequent occurrence of other organ specific auto- immune diseases in
affected individuals or in their family members.
Approximately 85% of patients have circulating islet cell antibodies, and the
majorities also have detectable anti-Insulin antibodies before receiving Insulin
therapy. Most Islet cell antibodies are directed against Glutamic Acid Decarboxylase
(GAD) within pancreatic β cells.
 TYPE II DIABETESMELLITUS:
The two main pathological defects in Type II Diabetes are impaired Insulin
secretion through a dysfunction of the pancreatic β-cell, and impaired Insulin action
through Insulin resistance. In situations where resistance to Insulin predominates, the
mass of β-cells undergoes a transformation capable of increasing the Insulin supply
and compensating for the excessive and anomalous demand.
In absolute terms, the plasma Insulin concentration (both fasting and meal
stimulated) usually is increased but although relative to the severity of Insulin
resistance, the plasma Insulin concentration is insufficient to maintain normal Glucose
Homeostasis. Keeping in mind the intimate relationship between the secretion of
Insulin and the sensitivity of hormone action in the complicated control of Glucose
Homeostasis, it is practically impossible to separate the contribution of each to the
etiopathogenesis of Diabetes Mellitus type II.
Insulin resistance and HyperInsulinemia eventually lead to Impaired Glucose
Tolerance. Except for Maturity Onset Diabetes of the Young(MODY), the mode of
inheritance for Type II Diabetes Mellitus is unclear. MODY, inherited as an
autosomal dominant trait, may result from mutations in Glucokinase gene on
chromosome 7p. MODY is defined as Hyperglycaemia diagnosed before the age of
twenty-five years and treatable for over five years without Insulin in cases where Islet
cell antibodies (ICA) are negative.
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 INSULIN RESISTANCE:
The primary events are believed to be an initial deficit in Insulin secretion and
in many patients relative Insulin deficiency in association with peripheral Insulin
resistance. Resistance to the action of Insulin will result in impaired Insulin mediated
glucose uptake in the periphery (by muscle and fat), incomplete suppression of
hepatic glucose output and impaired triglyceride uptake by fat. To overcome the
Insulin resistance, Islet cells will increase the amount of Insulin secreted. Endogenous
glucose production is accelerated in patients with Type II Diabetes or Impaired
Fasting Glucose. Because this increase occurs in the presence of Hyper Insulinemia,
at least in the early and intermediate disease stages, hepatic Insulin resistance is the
driving force of Hyperglycaemia of Type II Diabetes. [60]
THE PANCREAS:
The Pancreas is an Abdominal Glandular organ, with a Digestive (Exocrine)
and Hormonal (Endocrine) function.
 ANATOMICAL POSITION:
The Pancreas is an oblong-shaped and flattened organ, about the size of a
hand. Aside from the tail, it is a Retroperitoneal structure (lies behind the peritoneal
cavity), located deep within the upper abdomen in the epigastrium and left
hypochodrium regions.
Within the abdomen, the Pancreas is surrounded by other viscera and vessels.
 Stomach – lies Anteriorly and Superiorly.
 Duodenum – situated Anteriorly and Medially, curving around the head of the
Pancreas.
 Spleen – located Posteriorly and Laterally. It is connected by ligaments to the
tail of the Pancreas.
 Vasculature – the Aorta and Inferior vena cava pass Posteriorly to the head of
the Pancreas.
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ANTERIOR VIEW OF ABDOMEN
 ANATOMICAL STRUCTURE:
The Pancreas is typically divided into five parts:
1. Head:
This is the widest part of the Pancreas. It lies within the C-shaped curve created
by the Duodenum, and is connected to it by connective tissue.
2. Uncinate process:
This is a projection arising from the lower part of the head and extending
medially to lie beneath the body of the Pancreas. It lies posterior to the superior
mesenteric vessels.
3. Neck:
Located between the head and the body of the Pancreas. It overlies the superior
Mesenteric vessels which form a groove in its posterior aspect.
4. Body:
The body is centrally located, crossing the midline of the human body to
lie behind the Stomach and to the left of the Superior Mesenteric vessels.
5. Tail:
The left end of the Pancreas that lies within close proximity to the hilum of the
Spleen. It is contained within the Spleno -renal ligament with the Splenic
vessels. This is the only part of the Pancreas that is intraperitoneal.
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PARTS OF THE PANCREAS
 THE DUCT SYSTEM:
The Exocrine compartment is classified as a Serous gland. It is composed of
approximately a million ‘Berry-like’ clusters of cells called Acini, connected by short
intercalated ducts.
Intercalated duct cells beginning within Acini are called Centroacinar cells.
The intercalated ducts drain into a network of intralobular collecting ducts, which in
turn drain into the main Pancreatic duct.
The Pancreatic duct runs the length of the Pancreas and unites with the
common bile duct, forming the Hepato-pancreatic Ampulla of Vater. This structure
opens into the Duodenum.
Secretions into the Duodenum are controlled by a muscular valve, the sphincter
of Oddi. It surrounds the Ampulla of Vater, acting as a valve.
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EXOCRINE PANCREAS SECRETING INTO THE DUODENUM
 VASCULATURE:
The Pancreas is supplied by the Pancreatic branches of the Splenic artery. The
head is additionally supplied by the superior and inferior Pancreatico-duodenal
arteries which are branches of the Gastro-duodenal and superior Mesenteric arteries,
respectively.
Venous drainage of the head of the Pancreas is into the superior Mesenteric
branches of the Hepatic portal vein. The Pancreatic veins draining the rest of the
Pancreas do so into the Splenic vein.
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THE ARTERIAL SUPPLY AND VENOUS DRAINAGE OF THE PANCREAS
 LYMPHATICS:
The Pancreas is drained by lymphatic vessels that follow the arterial supply.
They empty into the Pancreatico- Splenal nodes and the pyloric nodes, which in turn
drain into the superior Mesenteric and Celiac lymph nodes.
 CELLS AND SECRETIONS OF THE PANCREATIC ISLETS:
The Pancreatic Islets each contain four varieties of cells:
1. The alpha cell produces the hormone Glucagon and makes up approximately
20  percent of each Islet. Glucagon plays an important role in blood Glucose
regulation, low blood glucose levels stimulate its release.
2. The beta cell produces the hormone Insulin and makes up approximately 75
percent of each Islet. Elevated blood Glucose levels stimulate the release of
Insulin.
3. The delta cell accounts for four percent of the Islet cells and secretes the
peptide hormone Somatostatin.  It is also released by the hypothalamus (as
GHIH). Pancreatic Somatostatin inhibits the release of both
Glucagon and Insulin.
4. The Pancreatic polypeptide cell accounts for about one percent of Islet cells and
secretes the pancreatic polypeptide hormone. It is thought to play a role in
appetite, as well as in the regulation of Pancreatic Exocrine and Endocrine
secretions. Pancreatic polypeptide released following a meal may reduce
further food consumption, however, it is also released in response to fasting.
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 REGULATION OF BLOOD GLUCOSE LEVELS BY INSULIN AND
GLUCAGON:
Glucose is required for cellular respiration and is the preferred fuel for all
body cells. The body derives glucose from the breakdown of the carbohydrate-
containing foods and drinks. Glucose not immediately taken up by cells for fuel
can be stored by the liver and muscles as Glycogen, or converted to Triglycerides
and stored in the adipose tissue. Hormones regulate both the storage and the
utilization of glucose as required. Receptors located in the Pancreas sense blood
glucose levels, and subsequently the pancreatic cells secrete Glucagon or Insulin to
maintain normal levels.
 GLUCAGON:
 Receptors in the Pancreas can sense the decline in blood glucose levels, such
as during periods of fasting or during prolonged labour or exercise. In
response, the alpha cells of the Pancreas secrete the hormone Glucagon, which
has several effects:
 It stimulates the liver to convert its stores of glycogen back into glucose. This
response is known as Glycogenolysis. The glucose is then released into the
circulation for use by body cells.
 It stimulates the liver to take up amino acids from the blood and convert them
into glucose. This response is known as Gluconeogenesis.
 It stimulates Lipolysis, the breakdown of stored Triglycerides into free Fatty
acids and Glycerol. Some of the free glycerol released into the bloodstream
travels to the liver, which converts it into glucose. This is also a form of
Gluconeogenesis.
 These actions increase blood glucose levels. The activity of Glucagon is
regulated through a Negative feedback mechanism, rising blood glucose levels
inhibit further Glucagon production and secretion.
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 INSULIN:
The primary function of Insulin is to facilitate the uptake of glucose into body
cells. Red blood cells, as well as cells of the brain, liver, kidneys, and the lining of
the small intestine, do not have Insulin receptors on their cell membranes and do
not require Insulin for glucose uptake. Although all other body cells do require
Insulin if they are to take glucose from the bloodstream, skeletal muscle cells and
adipose cells are the primary targets of Insulin.
The presence of food in the intestine triggers the release of gastrointestinal
tract hormones such as glucose-dependent insulinotropic peptide (previously
known as Gastric inhibitory peptide). This is in turn the initial trigger for Insulin
production and secretion by the beta cells of the Pancreas. Once nutrient absorption
occurs, the resulting surge in blood glucose levels further stimulates Insulin
secretion.
Precisely how Insulin facilitates glucose uptake is not entirely clear. However,
insulin appears to activate a Tyrosine kinase receptor, triggering the
phosphorylation of many substrates within the cell. These multiple biochemical
reactions converge to support the movement of intracellular vesicles containing
facilitative glucose transporters to the cell membrane. In the absence of Insulin,
these transport proteins are normally recycled slowly between the cell membrane
and cell interior. Insulin triggers the rapid movement of a pool of glucose
transporter vesicles to the cell membrane, where they fuse and expose the glucose
transporters to the extracellular fluid. The transporters then move glucose by
facilitated diffusion into the cell interior. [61]
CLASSIFICATION
The new classification is primarily based on etiologies. The staging of patho-
physiology by degree of deficiency of insulin is also adopted. The previous terms,
insulin-dependent diabetes mellitus (IDDM) and non-insulin dependent diabetes
mellitus (NIDDM), are abandoned. Instead, the terms type 1 and type 2 diabetes
mellitus are used for etiological classification. The etiologic classifications of
Diabetes Mellitus are listed below.
Page | 47
TYPE I DIABETES:
Type I Diabetes Mellitus (Juvenile Diabetes) is characterized by betacell
destruction caused by an autoimmune process, usually leading to absolute Insulin
deficiency. Type I is usually characterized by the presence of anti–glutamic acid
decarboxylase, Islet cell or Insulin antibodies which identify the autoimmune
processes that lead to betacell destruction.
 IMMUNE-MEDIATED DIABETES:
This form of Diabetes, which accounts for only 5–10% of those with Diabetes,
previously encompassed by the terms Insulin-Dependent Diabetes. Type I Diabetes or
Juvenile-onset Diabetes, results from a cellular-mediated autoimmune destruction of
the β-cells of the Pancreas.
In this form of Diabetes, the rate of β-cell destruction is quite variable, being
rapid in some individuals (mainly infants and children) and slow in others (mainly
adults). Some patients, particularly children and adolescents, may present with
ketoacidosis as the first manifestation of the disease. Others have modest fasting
hyperglycaemia that can rapidly change to severe Hyperglycaemia and/or
ketoacidosis in the presence of infection or other stress.
 IDIOPATHIC DIABETES:
Some forms of Type I Diabetes have no known etiologies. Some of these
patients have permanent insulinopenia and are prone to ketoacidosis, but have no
evidence of autoimmunity. Although only a minority of patients with Type I Diabetes
fall into this category most are of African or Asian ancestry. Individuals with this
form of Diabetes suffer from episodic Ketoacidosis and exhibit varying degrees of
insulin deficiency between episodes.
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TYPE II DIABETES MELLITUS:
This form of Diabetes, which accounts for approximately 90–95% of those
with Diabetes, previously referred to as Non–Insulin-Dependent Diabetes, Type II
Diabetes, or Adult-Onset Diabetes, encompasses individuals who have Insulin
resistance and usually have relative (rather than absolute) insulin deficiency.
Most individuals with Type II Diabetes exhibit intra-abdominal (visceral)
obesity, which is closely related to the presence of Insulin resistance. In addition,
hypertension and dyslipidemia (high triglyceride and low HDL-cholesterol levels,
postprandial hyperlipidemia) often are present in these individuals.
This is the most common form of Diabetes Mellitus and is highly associated
with a family history of Diabetes, older age, obesity and lack of exercise. It is more
common in women, especially women with a history of Gestational Diabetes, and in
blacks, hispanics and native americans.
GESTATIONAL DIABETES MELLITUS (GDM):
Gestational Diabetes Mellitus is an operational classification (rather than a
pathophysiologic condition) identifying women who develop Diabetes Mellitus
during gestation. Women who develop Type I Diabetes Mellitus during pregnancy
and women with undiagnosed asymptomatic Type II Diabetes Mellitus that is
discovered during pregnancy are classified with Gestational Diabetes Mellitus
(GDM). In most women who develop GDM, the disorder has its onset in the third
trimester of pregnancy.
OTHER SPECIFIC TYPES:
 MONOGENIC DIABETES:
Types of Diabetes Mellitus of various known etiologies are grouped together to
form the classification called“Other Specific Types”. This group includes persons
with genetic defects of beta-cell function (this type of Diabetes was formerly called
MODY or Maturity-onset Diabetes in youth) or with defects of insulin action.
Persons with dysfunction associated with other endocrinopathies (e.g. Acromegaly),
and persons with pancreatic dysfunction caused by drugs, chemicals or infections and
they comprise less than 10% of DM cases. [62]
Page | 49
RISK FACTORS:
The risk factors for Type I Diabetes are still being researched. However,
having a family member with Type I Diabetes slightly increases the risk of
developing the disease. Environmental factors and exposure to some viral infections
have also been linked to the risk of developing Type I Diabetes.
Several risk factors have been associated with Type II Diabetes and include:
 Family history of Diabetes
 Overweight
 Unhealthy diet
 Physical inactivity
 Increasing age
 High Blood pressure
 Ethnicity
 History of Gestational Diabetes
 Poor nutrition during pregnancy
 Impaired Glucose Tolerance (IGT) is a category of higher than normal blood
glucose, but below the threshold for diagnosing Diabetes.
 Changes in diet and physical activity related to rapid development and
urbanisation have led to sharp increases in the numbers of people developing
Diabetes.
 Pregnant women who are overweight, have been diagnosed with IGT, or have
a family history of Diabetes are all at increased risk of developing Gestational
Diabetes Mellitus (GDM). In addition, having been previously diagnosed with
Gestational Diabetes or being of certain ethnic groups puts women at
increased risk of developing GDM. [63]
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CLINICAL FEATURES:
Most of the symptoms are similar in both types of Diabetes but they vary in
their degree and develop more rapidly in Type I Diabetes and more typical. Some of
the clinical features and symptoms are listed below.
 Glucosuria:
When blood glucose level is above 180mg/dl, glucose appears in urine. It is
the renal threshold for glucose.
 Osmotic Diuresis:
The excess glucose in renal tubules decreases reabsorbtion of water result in
diuresis. This leads to polyuria, polydipsia.
 Polyuria:
The amount of urine may be several litres in 24 hours. This is due to excessive
sugar in the urine which acts as a Diuretic.
 Polydipsia, Dryness of mouth:
Polyuria decreases water content in the body stimulates taste centre and in
turn increases water intake.
 Polyphagia and Predilection for sweet food:
This symptom is due to non utilization of sugar for energy expenditure.
 Asthenia:
This is due to proteins depletion and increased utilization of proteins for
energy.
 Emaciation:
It is due to loss of water, glycogen and triglyceride and proteins stores and
gradually reduced muscle mass occurs.
 Pruritis vulvae ,Balanitis, Genital Candidiasis, Skin Sepsis (Boils):
This is due to irritant action of sugar on the tissue and fungal or bacterial
infections.
 Constipation:
The stool becomes hard and bowel movement may take place after every 2 to
3 days.
 Nausea, Headache, Blurring of Vision,
 Mood change, Irritability, Difficulty in concentrating, Apathy, Unhealed wounds.
 Frequent changes in Refractive error and Cataract. [64]
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COMPLICATIONS:
People with Diabetes have an increased risk of developing a number of serious
health problems. Consistently high blood glucose levels can lead to serious diseases
affecting the heart and blood vessels, eyes, kidneys, nerves and teeth. In addition,
people with Diabetes also have a higher risk of developing infections. In almost all
high-income countries, Diabetes is a leading cause of cardiovascular
disease, blindness, kidney failure, andlower limb amputation.
Maintaining blood glucose levels, blood pressure, and cholesterol at or close
to normal can help delay or prevent Diabetes complications. Therefore people with
Diabetes need regular monitoring.
 CARDIOVASCULAR DISEASE:
Affects the heart and blood vessels and may cause fatal complications such as
Coronary Artery Disease (leading to heart attack) and Stroke. Cardiovascular Disease
is the most common cause of death in people with Diabetes. High blood pressure,
high cholesterol, high blood glucose and other risk factors contribute to increasing the
risk of cardiovascular complications.
 DIABETIC NEPHROPATHY:
This is caused by damage to small blood vessels in the kidney’s leading to
becoming less efficient or to fail altogether. Kidney disease is much more common in
people with Diabetes than in those without Diabetes. Maintaining near normal levels
of blood glucose and blood pressure can greatly reduce the risk of kidney disease.
 DIABETIC NEUROPATHY:
Diabetes can cause damage to the nerves throughout the body when blood glucose
and blood pressure are too high. This can lead to problems with digestion, erectile
dysfunction, and many other functions. Among the most commonly affected areas are
the extremities, in particular the feet. Nerve damage in these areas is called Peripheral
Neuropathy, and can lead to pain, tingling, and loss of feeling. Loss of feeling is
particularly important because it can allow injuries to go unnoticed, leading to serious
infections and possible amputations. People with Diabetes carry a risk of amputation
that may be more than 25 times greater than that of people without Diabetes.
However, with comprehensive management, a large proportion of amputations related
to Diabetes can be prevented. Even when amputation takes place, the remaining leg
and the person’s life can be saved by good follow-up care from a multidisciplinary
foot team. People with Diabetes should regularly examine their feet.
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 DIABETIC RETINOPATHY:
Most people with Diabetes will develop some form of Eye disease
(Retinopathy) causing reduced vision or blindness. Consistently high levels of blood
glucose, together with high blood pressure and high cholesterol, are the main causes
of Retinopathy. It can be managed through regular eye checks and keeping glucose
and lipid levels at or close to normal.
 FOOT DAMAGE:
Nerve damage in the feet or poor blood flow to the feet increases the risk of
various foot complications. Left untreated, cuts and blisters can develop serious
infections, which often heal poorly. These infections may ultimately require toe, foot
or leg amputation.
 SKIN CONDITIONS:
Diabetes may leave you more susceptible to skin problems, including bacterial
and fungal infections.
 HEARING IMPAIRMENT:
Hearing problems are more common in people with Diabetes.
 ALZHEIMER'S DISEASE:
Type II Diabetes may increase the risk of Alzheimer's disease. The poorer
your blood sugar control, the greater the risk appears.
 COMPLICATIONS OF GESTATIONAL DIABETES:
Most women who have Gestational Diabetes deliver healthy babies. However,
Untreated or Uncontrolled blood sugar levels can cause problems for mother and
baby.
I. PREGNANCY COMPLICATIONS:
Women with any Type of Diabetes during pregnancy risk a number of
complications if they do not carefully monitor and manage their
condition. To prevent possible organ damage to the foetus, women
with Type I Diabetes or Type II Diabetes should achieve target glucose
levels before conception.
II. SUBSEQUENT GESTATIONAL DIABETES:
Once you've Gestational Diabetes in one pregnancy, you're more likely
to have it again with the next pregnancy. [65]
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DIAGNOSIS:
Diabetes Mellitus refers to a condition in which circulating blood glucose is
chronically elevated. In Anaemia, there are many possible causes for a high blood
glucose. Equally, there can be wide variety of possible consequences, such that a
physician specializing in Diabetes must have some familiarity with almost every
system in the body. Investigation of Diabetes itself can be divided into the study of its
causes, natural history, epidemiology, genetic basis, pathophysiological mechanism
and biochemical consequences, and each of its many complications requires
investigating along similar lines. This entry provides a brief introduction to the way in
which research findings have over the years been translated into the clinical
investigation of Diabetes. [66]
 Blood:
1. Blood sugar estimation:
a. Blood sugar estimation is mandatory for confirming the diagnosis of
Diabetes.
b. Both fasting and postprandial blood sugar levels are estimated.
2. Criteria for diagnosis of Diabetes Mellitus:
a. Random blood sugar>200mg/dl on two occasions,
b. Fasting Plasma Glucose>126mg/dl and sustained elevation of plasma
glucose concentration>200mg/dl after an oral glucose load of 75gm at
2 hours.
3. Screening by Fasting Glucose test:
Fasting blood glucose determination is a screening test for Type II
Diabetes Mellitus. It is recommended for all above age of 45 yrs and
must be tested every 3 yrs and relatively earlier in overweight persons.
A fasting plasma glucose value above 126mg/dl is certainly indicative
of Diabetes Mellitus.
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INTERPRETATION (VENOUS PLASMA GLUCOSE):
Condition Fasting 2 hrs after Glucose load
1.Fasting Hyperglycaemia 110-125 mg/dl <140mg/dl
2.Impaired Glucose
Tolerance
<126mg/dl 140-199mg/dl
3.Diabetes >126mg/dl >200mg/dl
Impaired glucose patients have increased risk of progression to frank Diabetes and
Macrovascular atheromatous disease and kept under observation for repeating the test.
GLYCOSYLATED HAEMOGLOBIN (HbA1C):
Measurement of blood glucose level in Diabetics suffers from variation due to
dietary intake of the previous day. Glycated Haemoglobin (HbA1C) provides an
accurate and objective measure of glycaemic control over a period of weeks to
months. In Diabetes the slow non-enzymatic covalent attachment of glucose to
Haemoglobin (glycation) which takes place over 90-120 days that is lifespan of red
blood cells. So it gives an estimate of Diabetic control for the preceding 3-4
months.There is an increase in the amount of the HbA1 relative to Non-Glycated
Adult Haemoglobin.
 Advantages of HbA1C:
1. No dietary preparation or fasting is required
2. Increased (HbA1C) value certainly means Diabetes Mellitus, but normal value
does not rule out IGT
3. It is not used to diagnose Diabetes but it gives idea about poor control and
development of microvascular complications.
 Normal value:
Below 7 %
HbA1C diminished in
1. Anaemia
2. During pregnancy
3. Uraemia
4. Hemoglobinopathies
5. Blood transfusions.
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C-PEPTIDE ASSAY:
C-peptide is released into circulation during conversion of proinsulin to insulin
which is more sensitive than insulin assay.
OTHER INVESTIGATIONS:
1. Lipid profile
2. Liver function test
3. Blood urea
4. Serum Creatinine
 URINE:
Glucose:
a. Testing the urine for glucose with dipsticks is a common screening
procedure
b. for detecting Diabetes.
c. Performed on urine passed 1-2 hrs after meal to maximize sensitivity.
d. Glycosuria warrants further assessment by blood testing.
Common cause for Glycosuria :
Low renal threshold which also occur in pregnancy,
starvation, raised intracranial tension (cerebral tumours, haemorrhage
and head injury) and alimentary glycosuria.
Renal Glycosuria:
Normal renal threshold for glucose is below 180 mg/dl but glucose still
appear in urine due to low renal threshold. It is benign condition
unrelated to Diabetes Mellitus and runs in families, also in pregnancy.
Alimentary Glycosuria:
A rapid and transitory rise in blood glucose level after meal above the
normal renal threshold is called lag storage curve or alimentary
glycosuria and returns to normal after 2 hrs.
Ketones:
Test for Ketone bodies is for assessing severity of Diabetes and not
diagnosis of disease. If Glycosuria and Ketonuria are present,
diagnosis of diabetes is certain, Ketonuria also seen in fasting,
strenuous exercise, diet rich in fat and low in carbohydrate.
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Proteins:
Microalbuminuria or Proteinuria in absence of urinary tract infection is
an indicator of development of Diabetic Nephropathy and other
macrovascular complications. [67]
MANAGEMENT:
The management of Type I and II DiabetesMellitus (DM) requires addressing
multiple goals, with the primary goal being glycemic control. Maintaining glycemic
control in patients with Diabetes prevents many of the microvascular and
macrovascular complications associated with Diabetes. This chapter presents a review
of the prevalence, screening, diagnosis, and management of these complications.
 MICROVASCULAR:
Microvascular complications of Diabetes are those long-term complications
that affect small blood vessels. These typically include Retinopathy, Nephropathy,
and Neuropathy.
 Diabetic Retinopathy is divided into two main categories:
Non-proliferative Retinopathy and Proliferative Retinopathy.
 Non-proliferative Retinopathy is the development of Microaneurysms,
venous loops, Retinal Haemorrhages, hard exudates, and soft exudates.
 Proliferative Retinopathy is the presence of new blood vessels, with or
without vitreous Haemorrhage. It is a progression of Non-Proliferative
Retinopathy.
 Diabetic Nephropathy is defined as persistent Proteinuria, which is
characterized by progressive decline in renal function resulting in end-stage
renal disease.
 Diabetic Neuropathy is a heterogeneous condition associated with nerve
pathology. The condition is classified according to the nerves affected and
includes focal, diffuse, sensory, motor, and autonomic Neuropathy.
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 MACROVASCULAR:
Macrovascular complications of Diabetes are primarily diseases of the
coronary arteries, peripheral arteries, and cerebrovasculature. Early macrovascular
disease is associated with atherosclerotic plaque in the vasculature supplying blood to
the heart, brain, limbs, and other organs. Late stages of macrovascular disease involve
complete obstruction of these vessels, which can increase the risks of Myocardial
Infarction (MI), stroke, claudication, and gangrene. CardioVascular Disease (CVD) is
the major cause of morbidity and mortality in patients with Diabetes.
The aim of treatment is to achieve normal blood glucose levels, to alleviate
symptoms and to prevent complications.
The four pillars of Diabetic management are,
1. Diet
2. Exercise
3. Drugs –Oral hypoglycaemic agents and Insulin therapy by regular monitoring
of glycaemic control.
4. Early detection and treatment of complications. [68]
1. DIET:
It is the cornerstone of management of Diabetes.The objective is to have good
glycaemic control and to provide a nutritious and balanced diet. In Type II Diabetes
the calories need to be restricted in order to avoid obesity.
Total Caloric Intake:
It depends on body weight, degree of physical activity and presence of
Co - morbid illness.
Body Mass Index (BMI):
It determines the total caloric requirement
BMI= Weight (in kg) / Height in m2.
BMI Normal Range:
22- 25
The calories are derived from three principal sources like carbohydrates,
proteins and fats.
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Carbohydrates:
The amount of carbohydrate recommended in the diet is upto 50-60%. Whole
grains, ragi, wheat, millets, oats, brown rice which have low glycaemic index are
recommended.
Proteins:
Recommended amount is 12-20% of total calorie intake. Dhals or grams with
outer skin and sprouts, lean meat, fish, egg white and chicken are preferred.
Fat:
It should be 20-24% of total intake. Sunfloweroil, gingely oil, safflower oil,
olive oil rich in Mono and Polyunsaturated fats are advised. Palm oil, coconut oil and
vanaspathi should be avoided.
Salt:
Dietary salt should be less than 6g/day.
Milk and Milk Products:
Contribute to 40-45% of total fat content of vegetarian diet. Skimmed milk,
unsweetened yogurt, curd, buttermilk are recommended.
Vegetables:
Fibre rich in greens, brinjal, cauliflower, gourds and salads are advised.
PHYSICAL ACTIVITY:
Exercise forms an important component along with drugs and diet
management in Type II Diabetes Mellitus. Patients should be encouraged to take
regular physical activity in form of walking, jogging, swimming, gardening and
cycling for 30 minutes daily. This improves insulin sensitivity, prevents complications
of Diabetes, and assist in maintaining lipid profile and blood pressure, improves
muscle strength and beneficial for mental state of the individual. [69]
TRIAL DRUG
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PREPARATION OF TRIAL DRUG
Drug Name - Pungampoo Chooranam
Ingredients - Pungam flowers
Cow’s Ghee
Standard Operative Procedure:
The shade dried flowers of Pungam tree are roasted slowly by adding little bit
of cow’s ghee. Then it is powdered and sieved using cloth.
Dosage : 2 gm/ Bd
Adjuvant : Warm water
Duration : 48 Days
Text Reference - Boga Munivar Vaithiyam – 700
LITERATURE REVIEW OF PUNGAMPOO CHOORANAM
பார பா ேமகமி  ப தீர
பா கி ேற க ெவ ற
ேநர பா ஒ ப  வாாிவ
ேநயமா யா ெத  பா ட தி
ேசர பா வ ேப றி ெயாி  கி
சிற பாக வாவிென ப  தாென
ஊர பா வ ம ேபா ெகா ச  ெகா ச
உ ணஉ ண பா ேம ர வா ேக
வா கிேய ெயா ேநர  ெவ க
ம டல தா  ெகா டேவ ய ேநாெய லா
ஏ கிேய ேமகவைக ெய லா ேமா
இல ப ட தீ ேபால ெவாி ேபா
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பா கிேய ப திய தா  பகர ேக
பசிவான ளி ைக  த ளேவ
ஈ கியேதா  வா ெவ ற பதா த த ளி
இ சாப தியமாக  ேதேற
- ேபாக னிவ  ைவ திய 700 [70]
Botanical name - Pongamia pinnata
Family - Fabaceae (Papilionaceae)
Part used - Flower
Taste (Suvai) - Kaippu
Nature (Thanmai) - Veppam
Classification (Pirivu)- Kaarppu
Action - Astringent, Alternative, Parasiticide
CHEMICAL CONSTITUENTS:
 Karanjin
 Pongapin
 3 - Methoxypongapin
 Pongaglobrone
 Kanjone
 Pongol
 Gamatin
 Lanceolatin 3
 Pinnatin
 5 – Methoxy – 3’, 4’ Methylenedioxyfurano
 Ionchocarpin
 Isolonchocarpin
 Karanjachromene
 Pongachromene
 Isopongachromene
 Pongaflavone
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 Isopongaflavone
 Ovalichromene B
 Pongamol
 Ovalitenone
 Glabrin
 Kanugin
 Cemethoxykanugin
 Fisetintetramethylether
 Glabrachalcone
 Glabrachalcone – I
 Glabrachalcone – II
 Pongachalcone – I
 Pongachalcone – II
 Isopongaglabol
 Β – Sitosterol
 Quercetin glycoside
 Kaempferol and its glycoside
 Pongamin
 Neoglabrin
 Glabrasaponin
 Sterolin
 Fatty acid of the seed oil has been reported.
The aqueous extract of PongammiaPinnata flowers shows Antidiabetic
activity in streptozotocin induced diabetic rats.
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COW’S GHEE:
Pasu Nei Gunam:
தாக ழைலக க ச தி பி த வா பிர
ேமக  வயி ெறாி  வி கலழ - மாகாச
ம  வற சி ட ர ட ல தி க
ெசா ல  ேபா நிைர . [71]
Thanmai - Thatpam.
CHEMICAL CONSTITUENTS:
Saturated fatty acids
Triglycerides
Diglycerides
Monoglycerides
Phospholipids
Beta carotene 600 IU and vitamin E.
Action:
It controls thirst, vomiting, excessive pitha, burning sensation of the stomach,
pitha hiccup, abdominal pain, dryness, prickly heat, cough, hyper motility of the gut,
weakness of bones, haemorrhoids etc.
Page | 63
TRIAL DRUG – PUNGAMPOO CHOORANAM
DRIED PUNGAM FLOWERS COW’S GHEE
PUNGAMPOO CHOORANAM
MATERIALS
AND
METHODS
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MATERIALS AND METHODS
STUDY DESIGN:
The clinical trial on Madhumegam (Diabetes Mellitus – Type II) was decided
to conduct as an open label study.
STUDY CENTER:
The entire study was conducted on patients at Out Patient Department of Govt
Siddha Medical College, Chennai in the premises of Arignar Anna government hospital
for Indian medicine and Homeopathy, Arumbakkam, Chennai-106, during the period of
2015-2017.
DATA COLLECTION:
Literary evidence from various,
 Siddha books
 Modern books
 Medical journals
 Internet
POPULATION:
The Population consists of Diabetes accompanied by Polyuria, Polyphagia,
Polydipsia, generalised tiredness, Fatigue, Peripheral neuritis, Itching all over the body
and satisfying the inclusion and exclusion criteria mentioned below.
SAMPLE SIZE:
40 patients.
INCLUSION CRITERIA:
 Newly identified Type II Diabetic cases only.
 Subject within 30-60 years.
 Blood  Glucose (F) – 126mg/dl  to  140 mg/dl
 Blood  Glucose (pp) - 180mg/dl to  280 mg/dl
 HbA1C - 6.5% to 8%
 Polyuria
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 Polyphagia
 Polydipsia
 Nocturia
 Fatigue
EXCLUSION CRITERIA (BASED ON CLINICAL HISTORY):
 H/O Insulin Dependent Diabetes Mellitus (IDDM).
 H/O Cardiovascular Disease.
 H/O Diabetic Nephropathy.
 H/O Diabetic Retinopathy.
 Pregnant women, lactating mothers, T.B affected individuals.
DURATION OF TREATMENT:
48 days.
Patients were followed under the guidance and supervision of the
HOD, Professor, Reader, Lecturer and Assistant Lecturer of Maruthuvam, PG
Department, GSMC, Chennai-106.
The patients were carefully studied for their history, clinical
examinations, investigations and management.
EVALUATION OF CLINICAL PARAMETERS:
The history includes past, personal, family, occupation, dietary habits and
associated history.
CLINICAL INVESTIGATION:
 Blood:
Blood sugar (Fasting, Post Prandial)
Glycaemic control: HbA1C
Blood urea
Serum creatinine
Serum cholesterol
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 BMI (Body Mass Index)
 Urine:
Urine Sugar (Fasting, Postprandial)
SIDDHA ASSESSMENT:
Envagaithervugal
Neerkuri
Neikkuri
A case sheet format was prepared based on the Siddha methodology like
Envagaithervugal, Mukkutram, Nilam, Kaalam, Udalthathukkal including Neerkuri
and Neikuri. Individual case sheet was maintained for each patient at Outpatient
Department.
RESULTS
AND
OBSERVATION
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RESULTS AND OBSERVATION
The study on Madhumegam was carried out with 40 patients in the Out Patient
Department PG Maruthuvam, Govt Siddha Medical College attached to Arignar Anna
Govt hospital of Indian medicine, Chennai-106, during the period 2015-2017 were
analysed. The observation were made and tabulated with following criteria.
1. Age Distribution
2. Sex Distribution
3. Occupational Status
4. Socio economic Status
5. Dietary Habits
6. Family History
7. Kaalam
8. Paruva Kaalam
9. Thinnai
10. Duration of illness
11. Mukkutram - Vali, Azhal, Iyam
12. Ezhu Udalthathukkal
13. Ennvagai Thervugal
14. Naadi
15. Neikurai
16. Clinical features
17. Clinical Prognosis
18. Urine sugar - Fasting, PostPrandial
19. Blood Sugar - Fasting, PostPrandial
20. HbA1C Level
21. Grading of Results.
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1. AGE DISTRIBUTION
Age No. Of Cases Percentage
30 – 40 15 37.5%
41 – 50 19 47.5%
51 - 60 6 15%
Inference:
From selected 40 cases, 15 patients (37.5%) were between 30 - 40
years, 19 patients (47.5%) were between 41 – 50 years and 6 patients (15%) were
between 51 – 60 years old.
37.50%
47.50%
15%
0%
5%
10%
15%
20%
25%
30%
35%
40%
45%
50%
30 - 40 41 - 50 51 - 60
AGE DISTRIBUTION
30 - 40
41 - 50
51 - 60
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2. SEX DISTRIBUTION:
Sex No. Of Cases Percentage
Male 13 32.5%
Female 27 67.5%
Inference:
Out of 40 patients, 13 cases (32.5%) were male and 27 cases (67.5%)
were female.
32.5%
67.5%
SEX DISTRIBUTION
MALE
FEMALE
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3. OCCUPATIONAL STATUS:
Occupation No. Of Cases Percentage
House Wife 19 47.5%
Business 7 17.5%
Office Going 9 22.5%
Retired 5 12.5%
Inference:
From selected 40 cases, 19 patients (47.5%) were housewives, 7
patients (17.5%) are doing business, 9 patients (22.5%) are office goers and 5 (12.5%)
are retired.
47.50%
HOUSE WIFE
17.5%
22.50%
12.50%
OCCUPATION
BUSINESS OFFICE GOING RETIRED
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4. SOCIO ECONOMIC STATUS:
Socio Economic Status / Annum No. Of Cases Percentage
Poor (Upto Rs.2,00000) 13 32.5%
Middle Class ( Rs.2,00000- 5,00000) 20 50%
High Class ( Above Rs.5,00000) 7 17.5%
Inference:
Regarding Socio Economic Status 13 Patients (32.5%) comes under
Poor category, 20 patients (50%) come under Middle class and 7 Patients (17.5)
comes under High status.
32.5%
50%
17.5%
SOCIO ECONOMIC STATUS
Poor
Middle class
High status
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5. DIETARY HABITS:
Dietary Habits No. Of Cases Percentage
Vegetarian 8 20%
Mixed 32 80%
Inference:
Regarding Diet, out of 40 patients, 8 patients (20%) takes Vegetarian
diet and 32 patients (80%) takes mixed diet.
20%
80%
DIETARY HABITS
Vegetarian
Mixed
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6. FAMILY HISTORY:
Family History No. Of Cases Percentage
Father 6 15%
Mother 6 15%
No Relevant History 28 70%
Inference:
Regarding family history 6 patients (15%) fathers with diabetic, 6
patients (15%) mothers are diabetic and 28 patients (70%) have no relevant family
history.
15%
0%
10%
20%
30%
40%
50%
60%
70%
80%
FATHER
Per
cen
tag
e
15%
70%
MOTHER NO
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HISTORY
FAMILY HISTORY
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Page | 74
7. DISTRIBUTION OF KAALAM:
Kaalam No. Of Cases Percentage
Vaatha Kaalam
(0- 33 years) 2 5%
Pitha Kaalam
(34-66 years) 38 95%
Kabha Kaalam
(67-100 years) Nil 0%
Inference:
Out of 40 patients, 2 patients (5%) comes under Vaatha
Kaalam, 38 patients (95%) comes under Pitha Kaalam and no patients comes under
Kabha Kaalam.
0%
10%
20%
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40%
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8. PARUVA KAALAM:
Paruva Kaalam
(Seasons) Month No. Of Cases Percentage
Kaar Kaalam
Aavani, Purattasi (Mid
Aug- Mid Oct) 4 10%
Koothir Kaalam
Iyppasi, Karthigai (Mid
Oct – Mid Dec) 9 22.5%
Mun Pani Kaalam
Margazhi, Thai (Mid
Dec – Mid Feb) 18 45%
Pin Pani Kaalam
Maasi, Panguni (Mid
Feb – Mid Apr) 5 12.5%
Elavenil Kaalam
Chithirai, Vaigasi ( Mid
Apr – Mid June) 2 5%
Muthu Venil Kaalam
Aani, Aadi (Mid June –
Mid Aug) 2 5%
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Inference:
From selected 40 patients, 4 patients (10%) comes under Kaar Kaalam, 9
patients (22.5%) comes under Koothir Kaalam, 18 patients (45%) comes under Mun
Pani Kaalam, 5 patients (12.5%) comes under Pin Pani Kaalam, 2 patients (5%)
comes under Elavenil Kaalam and 2 patients (5%) comes under Muthuvenil Kaalam.
10%
22.50%
45%
12.50%
5% 5%
Percentage
PAARUVA KAALAM
Kaar Kaalam Koothir Mun Pani Pin Pani Elavenil Muthuvenil
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9. DISTRIBUTION OF THINAI:
Thinai No. Of Cases Percentage
Kurunji 0 0%
Mullai 0 0%
Marutham 0 0%
Neithal 40 100%
Paalai 0 0%
Inference:
All the 40 patients belongs to Neithal Nilam.
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10. DURATION OF ILLNESS:
Duration Of Illness No. Of Cases Percentage
Newly Identified patients 9 22.5%
3- 6 Months 31 77.5%
Inference:
Out of 40 patients, 9 patients (22.5%) belong to newly identified
category and 31 patients (77.5%) belongs to 3 – 6 months category.
DURATION OF ILLNESS
Newly Identified patients
3- 6 Months
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11. REFERENCE TO MUKKUTTRAM:
a. Affected Vali:
Classification Of Vali No. Of Cases Percentage
Praanan 0 0%
Abaanan 40 100%
Vyaanan 40 100%
Udhaanan 0 0%
Samaanan 40 100%
Naagan 0 0%
Koorman 6 15%
Kirugaran 40 100%
Devathathan 40 100%
Dhananjeyan NIL 0%
Inference:
From the selected 40 patients, all the 40 patients were affected with
Abaanan, Vyaanan, Samaanan, Kirugaran and Devathathan, 6 patients (15%) was
affected with Koorman and none affected with Praanan, Udhaanan, Naagan and
Dhananjeyan.
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b. Affected Azhal:
Classification Of Azhal No. Of Cases Percentage
Paasagam (Anal Pitham) 40 100%
Ranjagam 8 20%
Sadhagam 40 100%
Aalosagam 6 15%
Prasagam 4 10%
Inference:
Out of 40 patients, all the 40 patients were affected with Paasagam and
Saadhagam, 8 patients (20%) was affected with Ranjagam, 6 patients (15%) was
affected in Aalosagam and 4 patients (10%) was affected with Prasagam.
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c. Affected Iyyam:
Classification Of
Iyyam
No. of Cases Percentage
Avalambagam 0 0%
Kilethagam 40 100%
Pothagam 0 0%
Tharpagam 0 0%
Santhigam 26 65%
Inference:
Out of 40 patients, all patients were affected with Kilethagam,
Santhigam was affected in 26 patients (65%) and none affected with Avalambagam,
Pothagam and Tharpagam.
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12. EZHU UDAL THATHUKKAL:
Ezhu Udal Thathukkal No. Of Cases Percentage
Saaram 40 100%
Senneer 40 100%
Oon 4 10%
Kozhuppu 4 10%
Enbu 26 65%
Moolai 0 0%
Sukkilam/Suronitham 0 0%
Inference:
From the above chart, we observe that Saaram and Senneer were
affected in all the patients (100%), Oon & Kozhuppu was affected to the extent of
10% and Enbu affected in 26 patients (65%). None affected with Moolai and
Sukkilam.
100%
EZHU UDAL THATHUKKAL
Saaram Senneer
PERCENTAGE
100%
10% 10%
65%
0% 0%
Oon Kozhuppu Enbu Moolai Sukkilam/Suronitham
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13. ENN VAGAI THERVUGAL:
Enn Vagai Thervugal No. Of Cases Percentage
Naadi 40 100%
Sparisam 4 10%
Naa 40 100%
Niram 8 20%
Mozhi 0 0%
Vizhi 6 15%
Malam 8 20%
Moothiram 40 100%
Inference:
Regarding Enn Vagai Thervu, none was affected with Mozhi. 8
patients (20%) was Malam and Niram affected, Vizhi was affected in 6 patients
(15%), 4 patients (10%) was sparisam affected, Naadi, Naa and Moothiram was
affected for all the 40 patients.
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14. NAADI:
Naadi No. Of Cases Percentage
Pitha Vaatham 26 65%
Vaatha Pitham 8 20%
Pitha Kabham 6 15%
Inference:
Out of 40 patients, 26 patients (65%) had Pitha Vaatha naadi, 8
patients (20%) had Vaatha Pitha naadi and 6 patients (15%) had Pitha Kabha naadi.
PITHA VAATHAM
65%
20%
15%
NAADI
VAATHA PITHAM PITHA KABHAM
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15. NEI KURI REFERNCE:
Nei Kuri Character Of
Urine
No. Of Cases Percentage
Vaatha Neer Spreads like snake 10 25%
Pitha Neer Spreads like ring 20 50%
Kabha Neer Float like pearl 10 25%
Inference:
Out of 40 patients, 10 patients (25%) had Vaatha Neer, 20 patients
(50%) had Pitha Neer and 10 patients (25%) had Kabha Neer.
25%
50%
25%
Vaatha Neer Pitha Neer Kabha Neer
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16. CLINICAL FEATURES:
Signs &  Symptoms No. Of Cases Percentage
Polyuria 40 100%
Polyphagia 40 100%
Polydipsia 40 100%
Itching present all over the
body
4 10%
Pain all over the body 34 85%
Dryness of Mouth & Throat 40 100%
Constipation 8 20%
Emaciation 4 10%
Skin infection 4 10%
Disturbed Sleep 40 100%
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SIGNS & SYMPTOMS
Inference:
In respect of the patients with Mathumegam, the clinical symptoms of
Polyuria, Polyphagia, Polydipsia, Dryness of Mouth & Throat and Disturbed sleep
were present in all cases (100%). Itching all over the body, skin infection &
Emaciation in 4 patients (10%), Pain all over the body in 34 cases (85%),
Constipation in 8 patients (20%).
100% 100%
Polyuria
Polydipsia
Pain all over the body
Constipation
Skin infection
Percentage
100%
10%
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100%
Polyphagia
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17. CLINICAL PROGNOSIS:
Signs &
Symptoms
Before Treatment After Treatment
No. Of
Cases
Percentage No. Of
Cases
Percentage
Polyuria 40 100% 7 17.5%
Polyphagia 40 100% 5 12.5%
Polydipsia 40 100% 4 10%
Itching present
all over the
body
4 10% 0 0%
Pain all over the
body
34 85% 7 17.5%
Dryness of
Mouth & Throat
40 100% 0 0%
Constipation 8 20% 0 0%
Emaciation 4 10% 3 7.5%
Skin infection 4 10% 0 0%
Disturbed Sleep 40 100% 4 10%
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SIGNS & SYMPTOMS
Inference:
The clinical signs & symptoms were improved after treatment,
showing only 17.5% of people have Polyuria, 12.5% have Polyphagia, 10% of people
have Polydipsia, 17.5% had pain all over the body, 10% have skin infection and 10%
had disturbed sleep 7.5% had emaciation. The symptoms of Itching all over the body,
dryness in Mouth & Throat, constipation, skin infection were completely relieved.
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18.A) BLOOD SUGAR (FASTING):
Blood
Sugar
mg/dl
Before
Treatment
(No. Of Cases)
Percentage After Treatment
(No. Of Cases)
Percentage
<126 0 0% 38 95%
126-130 12 30% 2 5%
131-140 28 70% 0 0%
Inference:
Fasting blood sugar has controlled by 95% of cases.
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18.(B) BLOOD SUGAR (POST PRANDIAL):
Blood
Sugar
mg/dl
Before
Treatment
(No. Of Cases)
Percentage After Treatment
(No. Of Cases)
Percentage
<179 0 0% 20 50%
180-199 6 15% 15 37.5%
>200 34 85% 5 12.5%
Inference:
The Blood Sugar Post Prandial has controlled by 87.5% of cases.
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19.(A)URINE SUGAR (FASTING)
Urine
Sugar
Before
Treatment
(No. Of Cases)
Percentage After
Treatment
(No. Of Cases)
Percentage
(+) 7 17.5% 2 5%
NIL 33 82.5% 38 95%
Inference:
From the above chart it may be observed that urine sugar position on
fasting after treatment had improved drastically. And it was nil in 95% of cases after
treatment.
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19.  (B) URINE SUGAR (POST PRANDIAL):
Urine
Sugar
Before Treatment
(No. Of Cases)
Percentage After Treatment
(No. Of Cases)
Percentage
(++) 7 17.5% 0 0%
(+) 27 68.5% 4 10%
NIL 6 15% 36 90%
Inference:
It may be noted that post prandial urine sugar position after treatment
had improved drastically. It was nil in 90% of cases after treatment.
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20. HBA1C LEVEL:
HBA1C Before
Treatment
(No. Of
Cases)
Percentage After
Treatment
(No. Of Cases)
Percentage
Pre-
Diabetes
0 0% 06 15%
Good
Control
14 35% 24 60%
Fair Control 26 65% 10 25%
Inference:
HBA1C level has good control in 75% of cases and fair control in 25%
of cases after treatment.
0%
15%
0%
10%
20%
30%
40%
50%
60%
70%
35%
65%
60%
25%
HBA1C LEVEL
Before Treatment
After Treatment
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21. (A). BASED ON REDUCTION IN BLOOD SUGAR
FASTING:
Blood Sugar Level
(F)
Prognosis No. Of Cases Percentage
30 – 40 mg/dl Good 7 17.5%
21 – 29 mg/dl Moderate 18 45%
< 20 mg/dl Mild 15 37.5%
Inference:
Out of 40 patients, 7 patients (17.5%) shows good result, 18 patients
(45%) shows moderate results and 15 patients (37.5%) shows mild results.
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15%
20%
25%
30%
35%
40%
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50%
Good Moderate Mild
30 – 40 mg/dl 21 – 29 mg/dl < 20 mg/dl
30 – 40 mg/dl Good
21 – 29 mg/dl Moderate
< 20 mg/dl Mild
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21 (B). BASED ON REDUCTION IN BLOOD SUGAR POST
PRANDIAL:
Blood Sugar
Level (PP)
Prognosis No. Of Cases Percentage
51 - 75 mg/dl Good 7 17.5%
26 - 50 mg/dl Moderate 28 70%
< 25 mg/dl Mild 5 12.5%
Inference:
Out of 40 patients, 7 patients (17.5%) shows good result, 28 patients
(70%) shows moderate results and 5 patients (12.5%) shows mild results.
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BLOOD SUGAR LEVEL
S.NO OUT PATIENT
NO.
BLOOD SUGAR LEVEL
AGE/
SEX
BEFORE
TREATMENT
AFTER
TREATMENT
F
(mg/dl)
PP
(mg/dl)
F
(mg/dl)
PP
(mg/dl)
1 5994 40/F 132 231 110 193
2 4957 45/M 138 233 120 191
3 4948 40/M 136 221 122 188
4 5783 44/F 131 202 119 168
5 491 31/M 136 189 94 152
6 2194 48/M 139 242 124 218
7 2382 40/M 132 214 121 180
8 2452 40/F 129 230 97 188
9 5107 45/M 133 214 109 181
10 5402 38/F 130 219 106 186
11 6905 37/F 127 183 103 161
12 7529 50/F 140 263 132 217
13 7567 40/F 129 220 98 159
14 8031 37/F 126 227 98 161
15 8704 50/M 139 247 105 196
16 9008 35/F 133 188 111 143
17 9939 48/F 137 213 113 177
18 300 36/F 127 185 95 157
19 815 58/F 129 218 119 169
20 995 47/F 138 220 114 173
21 1379 47/F 133 203 120 171
22 1691 45/F 131 226 109 180
23 1692 48/F 128 214 94 179
24 1968 54/M 135 245 108 208
25 2008 55/F 138 253 122 188
26 7720 60/M 140 258 130 203
27 3100 50/F 136 206 121 174
28 3138 30/F 131 186 105 166
29 3436 47/M 128 219 108 179
30 4577 46/M 136 226 114 187
31 4612 50/F 128 221 106 176
32 4660 40/F 133 228 117 179
33 4664 38/M 130 219 102 186
34 4732 46/F 128 228 97 176
35 5280 55/F 138 257 119 221
36 5610 37/F 131 184 98 168
37 7617 45/M 136 231 112 173
38 8218 53/F 133 222 123 182
39 8252 44/F 131 229 113 197
40 8657 43/F 134 237 119 181
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BMI CHART OF THE PATIENTS
BEFORE TREATMENT AFTER TREATMENT
S.No O.P.No. Age/
Sex
Wt
(kg)
Ht (CM) BMI H/L/O Wt
(kg)
Ht
(CM)
BMI H/L/O
1 5994 40/F 62 162 23 H 60 162 23 H
2 4957 45/M 58 160 23 H 57 162 22 H
3 4948 40/M 60 163 23 H 57 163 22 H
4 5783 44/F 70 165 26 O 69 165 25 O
5 491 31/M 59 158 23 H 56 158 22 H
6 2194 48/M 59 163 22 H 57 163 22 H
7 2382 40/M 68 173 22 H 65 173 22 H
8 2452 40/F 62 160 24 H 60 162 23 H
9 5107 45/M 65 170 22 H 63 170 22 H
10 5402 38/F 63 163 24 H 60 163 23 H
11 6905 37/F 50 164 18 L 55 164 20 H
12 7529 50/F 80 175 26 O 77 175 25 O
13 7567 40/F 70 163 26 O 68 163 26 O
14 8031 37/F 70 189 24 H 74 189 21 H
15 8704 50/M 65 163 24 H 62 163 23 H
16 9008 35/F 60 162 22 H 58 162 22 H
17 9939 48/F 70 170 24 H 67 170 23 H
18 300 36/F 75 170 26 O 73 170 25 O
19 815 58/F 56 157 22 H 54 157 22 H
20 995 47/F 61 165 22 H 59 165 22 H
21 1379 47/F 63 163 24 H 62 163 23 H
22 1691 45/F 55 155 24 H 52 155 22 H
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BEFORE TREATMENT AFTER TREATMENT
S.No O.P.No. Age/
Sex
Wt
(kg)
Ht (CM) BMI H/L/O Wt
(kg)
Ht
(CM)
BMI H/L/O
23 1692 48/F 70 170 24 H 68 170 23 H
24 1968 54/M 50 163 18 L 54 163 20 H
25 2008 55/F 56 157 22 H 54 157 22 H
26 7720 60/M 61 165 22 H 59 165 22 H
27 3100 50/F 58 163 22 H 56 163 21 H
28 3138 30/F 75 170 27 O 73 170 25 O
29 3436 47/M 50 163 18 L 55 163 21 H
30 4577 46/M 61 165 21 H 59 165 22 H
31 4612 50/F 59 163 22 H 57 163 21 H
32 4660 40/F 55 155 22 H 53 155 22 H
33 4664 38/M 72 170 24 H 70 170 24 H
34 4732 46/F 50 163 18 L 55 163 21 H
35 5280 55/F 61 168 21 H 65 168 23 H
36 5610 37/F 50 163 18 L 53 163 20 H
37 7617 45/M 70 165 26 O 68 165 25 O
38 8218 53/F 62 165 24 H 60 165 22 H
39 8252 44/F 61 165 21 H 58 165 21 H
40 8657 43/F 59 163 22 H 56 163 21 H
H – Healthy L – Lean O - Overweight
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BIO CHEMICAL ANALYSIS OF THE PATIENTS
S.No O.P. NO. Age/
Sex
Blood Sugar Level (mg/dl) Urine Sugar Level HBA1C
BT AT BT AT
F PP F PP F PP F PP BT AT
1 5994 40/F 132 231 110 193 NIL (+) NIL NIL 7.1 6.4
2 4957 45/M 138 233 120 191 (+) (+) NIL NIL 7.3 6.2
3 4948 40/M 136 221 122 188 NIL (+) NIL NIL 7.0 6.3
4 5783 44/F 131 202 119 168 NIL (+) NIL NIL 6.9 6.4
5 491 31/M 136 189 94 152 NIL NIL NIL NIL 6.6 5.2
6 2194 48/M 139 242 124 218 (+) (++) NIL (+) 8.0 7.9
7 2382 40/M 132 214 121 180 NIL (+) NIL NIL 7.3 6.5
8 2452 40/F 129 230 97 188 NIL (+) NIL NIL 7.2 6.4
9 5107 45/M 133 214 109 181 NIL (+) NIL NIL 7.3 6.3
10 5402 38/F 130 219 106 186 NIL (+) NIL NIL 6.9 6.1
11 6905 37/F 127 183 103 161 NIL NIL NIL NIL 6.7 5.8
12 7529 50/F 140 263 132 217 (+) (++) (+) (+) 8.0 7.8
13 7567 40/F 129 220 98 159 NIL (+) NIL NIL 7.8 6.5
14 8031 37/F 126 227 98 161 NIL (+) NIL NIL 7.1 6.4
15 8704 50/M 139 247 105 196 (+) (++) NIL NIL 7.8 6.3
16 9008 35/F 133 188 111 143 NIL NIL NIL NIL 6.7 5.7
17 9939 48/F 137 213 113 177 NIL (+) NIL NIL 7.0 6.5
18 300 36/F 127 185 95 157 NIL NIL NIL NIL 6.8 5.7
19 815 58/F 129 218 119 169 NIL (+) NIL NIL 7.3 6.5
20 995 47/F 138 220 114 173 NIL (+) NIL NIL 7.4 6.8
21 1379 47/F 133 203 120 171 NIL (+) NIL NIL 6.8 6.4
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S.NO O.P.NO Age/
Sex
Blood Sugar Level (mg/dl) Urine Sugar Level
HBA1C
BT AT BT AT
F PP F PP F PP F PP BT AT
22 1691 45/F 131 226 109 180 NIL (+) NIL NIL 7.0 6.7
23 1692 48/F 128 214 94 179 NIL (+) NIL NIL 8.0 7.9
24 1968 54/M 135 245 108 208 NIL (++) NIL (+) 7.8 7.5
25 2008 55/F 138 253 122 188 NIL (++) NIL NIL 7.2 7.0
26 7720 60/M 140 258 130 203 (+) (++) (+) (+) 8.0 7.6
27 3100 50/F 136 206 121 174 (+) (+) NIL NIL 6.8 6.3
28 3138 30/F 131 186 105 166 NIL NIL NIL NIL 6.7 5.8
29 3436 47/M 128 219 108 179 NIL (+) NIL NIL 7.3 6.5
30 4577 46/M 136 226 114 187 NIL (+) NIL NIL 7.4 6.8
31 4612 50/F 128 221 106 176 NIL (+) NIL NIL 7.6 7.3
32 4660 40/F 133 228 117 179 NIL (+) NIL NIL 7.5 7.1
33 4664 38/M 130 219 102 186 NIL (+) NIL NIL 6.8 6.1
34 4732 46/F 128 228 97 176 NIL (+) NIL NIL 7.9 7.6
35 5280 55/F 138 257 119 221 (+) (++) NIL (+) 8.0 7.8
36 5610 37/F 131 184 98 168 NIL NIL NIL NIL 7.1 5.9
37 7617 45/M 136 231 112 173 NIL (+) NIL NIL 7.6 6.9
38 8218 53/F 133 222 123 182 NIL (+) NIL NIL 8.0 7.3
39 8252 44/F 131 229 113 197 NIL (+) NIL NIL 7.0 6.4
40 8657 43/F 134 237 119 181 NIL (+) NIL NIL 6.9 6.6
BT – Before Treatment, AT- After Treatment, N – Nil, F- Fasting, PP – Post Prandial
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LABORATORY INVESTIGATION REPORT OF THE PATIENTS
S.No OP .No Age/Sex
Blood Urea
(mg/dl)
Serum Creatinine
(mg/dl)
Total Cholesterol
(mg/dl)
BT AT BT AT BT AT
1 5994 40/F 26 23 0.6 0.7 176 172
2 4957 45/M 27 29 0.7 0.6 179 180
3 4948 40/M 32 30 0.86 0.82 174 180
4 5783 44/F 21 22 0.74 0.72 185 176
5 491 31/M 38 29 0.92 0.75 188 186
6 2194 48/M 42 40 0.9 0.86 179 181
7 2382 40/M 28 32 0.86 0.85 191 187
8 2452 40/F 39 21 0.86 0.61 179 178
9 5107 45/M 32 32 0.67 0.92 176 186
10 5402 38/F 31 29 0.72 0.69 167 189
11 6905 37/F 19 24 0.65 0.52 176 142
12 7529 50/F 24 24 0.72 0.69 161 184
13 7567 40/F 26 21 0.59 0.71 167 176
14 8031 37/F 26 24 0.74 0.81 166 149
15 8704 50/M 44 24 0.86 0.86 181 190
16 9008 35/F 36 23 0.86 0.67 187 166
17 9939 48/F 47 40 0.68 0.75 179 173
18 300 36/F 21 18 0.84 0.56 179 105
19 815 58/F 38 32 0.74 0.86 166 178
20 995 47/F 32 31 0.76 0.67 179 173
21 1379 47/F 13 23 0.78 0.65 180 178
22 1691 45/F 21 27 0.86 0.76 182 165
23 1692 48/F 35 32 0.68 0.85 176 175
24 1968 54/M 41 38 0.89 0.86 173 182
25 2008 55/F 26 29 0.68 0.81 186 176
26 7720 60/M 41 24 0.86 0.91 179 178
27 3100 50/F 40 20 0.91 0.62 186 151
28 3138 30/F 20 27 0.62 0.80 165 181
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S.No OP .No Age/Sex
Blood Urea
(mg/dl)
Serum Creatinine
(mg/dl)
Total Cholesterol
(mg/dl)
BT AT BT AT BT AT
29 3436 47/M 40 29 0.94 0.85 192 176
30 4577 46/M 23 29 0.89 0.80 190 167
31 4612 50/F 26 22 0.78 0.60 161 159
32 4660 40/F 26 28 0.82 0.70 172 160
33 4664 38/M 32 23 0.74 0.75 181 182
34 4732 46/F 31 21 0.82 0.60 188 180
35 5280 55/F 40 29 0.91 0.86 176 179
36 5610 37/F 32 18 0.86 0.75 169 181
37 7617 45/M 42 35 0.94 0.94 180 182
38 8218 53/F 40 28 0.86 0.75 179 186
39 8252 44/F 21 26 0.90 0.76 189 174
40 8657 43/F 28 23 0.74 0.73 160 159
BT – Before Treatment
AT – After Treatment
DISCUSSION
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DISCUSSION
Diabetes Mellitus, a group of metabolic disorder in which a person has high
blood sugar level, either because the pancreas does not produce enough Insulin, or
because cells do not respond to the Insulin that is produced. This high blood sugar
produces the classical symptoms of Polyuria (frequent urination), Polydipsia
(increased thirst) and Polyphagia (increased hunger).
Madhumegam is a clinical entity described by Yugi Munivar in ‘Yugi Vaithya
Chinthamani 800’ can be compared with Diabetes Mellitus-Type II. The classical
symptoms are Polyuria, Polyphagia, Polydipsia, itching all over the body and pain all
over the body.
Various Siddha literatures has been studied and discussed for choosing the
trial drug for treating Madhumegam and finally choosen “Pungampoo chooranam”,
which was mentioned in ‘Boga Munivar Vaithyam 700’.
Authentication is a critical step for successful and reliable clinical applications
and for further experimental studies on Siddha drugs.
DRUG AUTHENTICATION
Authentication of given specimen is the basic starting point in developing a
botanical product.
A sample of specimen is collected from farm near Vandavasi and its
organoleptic characters, Microscopic and Macroscopic examination was conducted
and authenticated by botanist from G.S.M.C. Chennai.
PHYSICOCHEMICAL ANALYSIS:
Physicochemical parameters includes
Loss on drying at 1050c - 9.24%
Total ash - 8.01%
Water soluble ash - 4.75%
Acid insoluble ash - 0.69%
Water soluble extractive - 26.46%
Alcohol soluble extractive - 29.35%
n - hexane soluble extractive - 19.26%
pH value (10%) - 7.5
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These values of the given sample were compared with the standard values of
Indian pharmacopoeia.
TOXICITY STUDY:
Toxicity studies in the animal models are done to determine and establish the
dose level recommended for the treatment of disease as drug. Both acute and sub-
acute toxicity studies are given special emphasis.
The experimental protocol was approved by The Institutional Animal Ethics
Committee of Sathyabama University, Chennai, Tamil Nadu, India.
IAEC Reference No: SU/CLATR/IAEC/IV/023/2016.
 Acute Toxicity Study
Acute toxicity study of the study drug Pungampoo Chooranam was carried out
as per OECD guideline (Organization for Economic Co-operation and Development)
Guideline-423. As a result of acute toxicity study no toxicity and mortality was found and
subsequent study has been conducted.
 Sub-Acute Toxicity Study
Sub-acute toxicity of the study drug Pungampoo Chooranam was carried out
as per OECD guideline-407. As a result of Sub-acute toxicity study no toxicity and
mortality was found.
Hematological analysis:
When compared to the control group, treatment groups has no
significant difference and hence treatment groups has no toxicity and
haematological differences.
Biochemical analysis:
No significant difference between control and treatment groups and
found no impacts in serological functions in treatment groups.
Histopathological evaluation:
Histopathology of vital organs like Liver, Kidney, Spleen and Lungs
were carried out. This evaluation shows no toxic effect in the trial
drug.
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Statistical analysis:
The statistical analysis was carried by one way ANOVA (GRAPH
PAD PRISM 5 computer program). Results were expressed as mean ±
standard error. A statistical comparison was carried out using the
Dunnet’s test for the control and treatment group.
Based on the analysis the results show nullified values between the control
group and treated groups.
PHARMACOLOGICAL EVALUATION:
The experimental protocol was approved by The Institutional Animal Ethics
Committee of Sathyabama University, Chennai, Tamil Nadu, India.
IAEC: SU/CLATR/IEAC/VII/051/2016.
Pharmacological studies of the trial drug Pungampoo Chooranam showed
ANTI DIABETIC ACTIVITY on tested animals.
BIO CHEMICAL ANALYSIS:
Biochemical assays are needed to evaluate disease models and to drive
biomarker analysis in translational medicine and clinical research.
Based on the analysis Pungampoo Chooranam exhibits the properties of
reducing sugar, alkaloids, zinc and potassium.
IEC:
IEC has approved my trial drug with the allowed sample size of 40 patients
with combined gender.
IEC No: GSMC-CH-ME-4/2015/009
CTRI:
The global mandate is to register all clinical trials prospectively, i.e. before the
enrolment of the first patient. I have successfully registered my trial drug by submitting the
details and scientific data’s to Clinical Trial Registry.
CTRI NO: CTRI/2017/02/007956
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CLINICAL STUDY:
Clinical studies were conducted followed by CTRI registration with the
sample size of 40 patients.
In my study, 40 patients with Madhumegam were selected in the Department
of Maruthuvam, Government Siddha Medical College, attached to Arignar Anna Govt
Hospital for Indian Medicine, Arumbakkam, Chennai - 106.
All necessary investigations were carried out to all patients and trial medicine
was given. The results of before and after treatment of all the patients were analysed
and discussed below.
 Age distribution:
o From selected 40 cases, 15 patients (37.5%) were between 30 - 40
years, 19 patients (47.5%) were between 41 – 50 years and 6 patients
(15%) were between 51 – 60 years old.
o Usually the non-insulin diabetes mellitus occurs only in the age group
above 45 years – International Diabetic Monitor.
 Sex distribution:
o Out of 40 patients, 13 cases (32.5%) were male and 27 cases (67.5%)
were female. Recent studies show that more women are prone to
diabetes than men.
 Occupational status:
o From selected 40 cases, 19 patients (47.5%) were housewives, 7
patients (17.5%) are doing business, 9 patients (22.5%) are office goers
and 5 (12.5%) are retired.
o Incidence of Madhumegam is more in housewives. Nowadays due to
modernisation and invention of electrical and electronic kitchen
equipments, the women lack physical exercise and results in more
prone to Madhumegam.
 Socio-economic status
o Regarding Socio Economic Status 13 Patients (32.5%) comes under
Poor category, 20 patients (50%) come under Middle class and 7
Patients (17.5) comes under High status.
o People belonging to lower group are more prone to Madhumegam.
Recent research indicates that the poor are more prone to diabetes.
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Research was being conducted to analyze whether rapid changes in
their lifestyle or the stress of poverty triggers diabetes.
 Dietary Habits:
o Regarding Diet, out of 40 patients, 8 patients (20%) takes vegetarian
diet and 32 patients (80%) takes mixed diet.
o Madhumegam is more incidences on non-vegetarians. Further it could
also be noted that people who are used fast and fried food are more
prone to diabetes as they have more calories of fat.
 Family history:
o Regarding family history 6 patients (15%) fathers with diabetic, 6
patients (15%) mothers are diabetic and 28 patients (70%) have no
relevant family history. Genetics plays an important role in
Madhumegam.
 Paruvakaalam:
o From selected 40 patients, 4 patients (10%) comes under Kaar Kaalam,
9 patients (22.5%) comes under Koothir Kaalam, 18 patients (45%)
comes under Mun Pani Kaalam, 5 patients (12.5%) comes under Pin
Pani Kaalam, 2 patients comes under Elavenil Kaalam and 2 patients
(5%) comes under Muthuvenil Kaalam.
o The seasonal variation has no impact on Madhumegam.
 Thinai:
o From the selected 40 patients, all (100%) comes under Neithal nilam .
 Body built:
o Regarding body built, 29 patients (72.5%) were having normal weight,
6 patients (15%) were overweight and 5 patients (12.5%) were lean.
 Duration of illness:
 Out of 40 patients, 9 patients (22.5%) belong to newly
identified category and 31 patients (77.5%) belong to 3 – 6
months category.
Page | 109
MUKKUTRAM CLASSIFICATION:
 In Vatham:
 Abanan affected in all patients (100%) causing Polyuria, Nocturia .
 Viyanan affected in all patients (100%) with Pain all over the body.
 Samanan and Kirukaran affected in all patients (100%) causing
Polyphagia.
 Devethathan affected in all patients (100%) causing disturbed sleep,
fatigue.
 Koorman affected in 6 patients (15%) causing dimness of vision.
 In Pitham:
 Paasagam affected in all patients (100%) causing polyphagia.
 Saadhagam affected in all patients (100%) causing lassitude.
 Ranjagam and Prasagam affected in (20%), (10%) patients causing pallor
and dry skin respectively.
 In Kabham:
 Kilethagam affected in all patients (100%) results in Polyphagia.
 Santhigam affected in 26 patients (65%) causing joint pain.
EZHU UDAL THATHUKKAL:
 Saaram affected in all patients (100%) results in tiredness, general debility.
 Senneer affected in all cases (100%) causing pallor, dryness.
 Oon and Kozhuppu affected in 4 patients (10%) each causing emaciation
 Enbu affected in 26 patients (65%) causing joint pain.
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ENVAGAI THERVUGAL:
 Naa, Naadi and Moothiram affected in all 40 patients (100%).
 Malam affected in 8 patients (20%) results in constipation.
 Sparisam affected in 4 patients (10%) causing dry skin.
 Niram affected in 8 patients (20%) results in pallor of the skin.
NAADI:
 26 patients (65%) had PithaVatha Naadi,
 8 patients (20%) had Vatha Pitha Naadi and
 6 patients (15%) had Pitha Kaba Naadi.
NEIKURI:
 10 patients (25%) had Vathaneer,
 20 patients (50%) had Pithaneer and
 10 patients (25%) had Kabhaneer.
SIGNS AND SYMPTOMS:
 Polyuria, Polyphagia, Polydipsia, dryness of the mouth and throat and
disturbed sleep present in all cases i.e 100%.
 Pain all over the body in 34 patients (85%),
 Itching in 10 patients (25%),
 Constipation in 8 patients (20%),
 Emaciation in 4 patients (10%) and
 Skin infection in10 cases (25%).
CLINICAL PROGNOSIS:
The clinical signs and symptoms were improved after treatment showing only
17.5% had polyuria, 12.5% had polyphagia, 10% of the people had polydipsia, 17.5%
have pain all over the body, and 10% had disturbed sleep. Itching all over the body,
skin infection, dryness of mouth and constipation were completely relieved.
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LABORATORY ASSESSMENT:
 Blood sugar Fasting:
o From the selected 40 patients, before treatment 28 patients are seen in
the range of 131-140mg/dl and after treatment 38 patients are seen
<126mg/dl.
 Blood sugar Post Prandial:
o From the selected 40 cases before treatment 34 patients seen
> 200 mg /dl and after treatment 20 patients post prandial
sugar level were < 179 mg/ dl.
 Urine sugar Fasting:
o From the selected 40 patients, before treatment 7 patients shows (+)
and 33 patients shows Nil. After treatment 2 patients are reduced to (+)
and 38 patients shows Nil Urine Sugar.
 Urine sugar Post Prandial:
o From the selected 40 patients, before treatment 27 patients show (+)
and 7 patients shows (++). After treatment 36 patients postprandial
urine sugar shows Nil.
 HbA1C:
o From the selected 40 cases all patients are seen in the range of
6.5- 8 %.  After treatment 30 patients had good control range of
6- 6.5 %.
SUVAI MUKKUTRAM THEORY:
Madhumegam is primarily due to derangement of Pitha kuttram. The trial
medicine Pungampoo Chooranam predominant with Thuvarppu suvai, it neutralises
the deranged pitham by Ethirurai Maruthuvam.
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BIO STATISTICAL ANALYSIS:
The p value is highly significant (p<0.001). So, there is significant reducing of
fasting, postprandial blood sugar level (mg) and HbA1C level among the patients for
the treatment of Madhumegam. Hence, it is concluded that treatment was effective
and significant.
GRADING OF RESULTS:
Out of 40 patients, 75% of cases showed Good result, 15% of the cases
showed Moderate result and 10 % showed minimal significance.
SUMMARY
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SUMMARY
The clinical study on Madhumegam was carried out in the Post Graduate
Department of Maruthuvam, Govt Siddha Medical College, Arignar Anna Hospital,
Chennai-106, during the period of 2015-2017.
A total of 40 patients were treated in the Out Patient Department (OPD). The
clinical and pathological assessment was carried out on the basis of both Siddha and
Modern aspects.
All the 40 patients were treated with Pungampoo Chooranam, 2g BD with
warm water for 48 days. The responses were assessed once in 7days for all the
patients.
 The peak incidence of Madhumegam was in the age group of 41-50 yrs
(47.5%) in both sexes.
 The prevalence was higher among the poor (32.5%).
 The disease is more common in housewives (47.5%).so high incidence occurs
in women.
 Regarding diet, the disease is seen among mixed dietary habits of about 80%.
 Regarding family history, 70% had no relavent history.
 Most of the patients were affected in Pitha kaalam (95%).
 In Vatham- Abaanan, Viyanan, Samanan, Kirukaran and Devathathan were
affected in all the cases 100%, Koorman was affected in 6 cases (15%).
 In Pitham-Analagam and Sathagam 100%, Ranjagam 20%, Alosagam 15%
and Prasagam 10% were affected.
 In Kabam- Kilethagam 100% and Santhigam 65% were affected.
 Among the Ezhu Udalthathukkal, Saaram, Seneer were 100% affected, Enbu
(65%), Oon (10%), Kozhuppu (10%) were affected.
 Regarding Envagaithervugal - Naa, Naadi and Moothiram were 100% affected
Niram, Malam (20%), Vizhi (15%), Sparisam (10%) were affected.
 Naadi - PithaVathanaadi (65%) was most commonly observed.
 ,In Neikuri examination, 50% Pithaneer were observed.
 The Toxicological study of Pungampoo Chooranam revealed no toxicity.
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 The pharmacological study shows Anti Diabetic Activity in streptozotocin
induced diabetic rats.
 Urine sugar Fasting and Postprandial became normal in 95% and 90% of
patients respectively.
 Regarding Blood sugar level, fasting and post prandial blood sugar reduced in
95% and 87.5% of the cases respectively.
 HbA1C level improved in 75% of cases which shows Good control in
Madhumegam.
 The clinical trial shows that there is significant improvement in clinical
manifestations of Madhumegam.
 The Biostatistical analysis of the clinical trial shows significant p-value
<0.001and hence the treatment was effective and significant.
CONCLUSION
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CONCLUSION
 Madhumegam is primarily due to derangement of Pitha kutram.
 The trial medicine Pungampoo Chooranam predominating with Thuvarppu
suvai, it neutralises the deranged pitham by Ethirurai Maruthuvam.
 Pungampoo Chooranam reveals no toxicity in animal models and hence
proved to be safe in human subjects.
 From preclinical Pharmacological studies, Pungampoo Chooranam has
Anti-Diabetic activity.
 No adverse effect was reported during the clinical study.
 Pungampoo Chooranam significantly reduced blood sugar level and also
reduced clinical features of Madhumegam.
 Pungampoo Chooranam is cost effective.
Hence I conclude that Pungampoo Chooranam will be a better drug that can be
used in the treatment of Madhumegam.
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TOXICITY STUDY 
 
ACUTE TOXICITY STUDY- OECD GUIDELINE – 423. 
IAEC NO: SU/CLATR/IAEC/IV/023/2016.  
Acute toxicity study of the study drug Pungampoo Chooranam was carried 
out as per OECD guideline (Organization for Economic Co-operation and 
Development) Guideline-423. 
Animal 
Healthy adult Wistar albino rat weighing between 170-200 g were used for the 
study.  The animals were housed in poly propylene cages and were kept in well 
ventilated with 100% fresh air by air handling unit (AHU). A 12 light / dark cycle 
were maintained .Room temperature was maintained between 22 + 20 C and relative 
humidity 50–65%. They were provided with food (Sai feeds, Bangalore, India) and 
water ad libitum. All the animals were acclimatized to the laboratory for 7 days prior 
to the start of the study. 
The experimental protocol was approved by The Institutional Animal Ethics 
Committee of Sathyabama University, Chennai, Tamil Nadu, India. 
Acute toxicity Study 
Acute toxicity study will be carried out in accordance with OECD guideline 423.[70] 
The animals were fasted overnight with free access to water. The study was conducted with 
single oral dose administration of Pungampoo Chooranam.  
Animal Grouping 
One group consist of 6 female rats were used for this study . The dose utilized 
for evaluation of acute toxicity study is about 2000 mg/kg higher than that of the 
therapeutic dose.  
Animal Grouping 
GROUP I: Animals received Test drug 2000 mg/kg (p.o)  
The animals were fasted overnight (12- 16 hrs) with free access to water. The 
study was conducted with single oral administration of study drugPungampoo 
Chooranam 2000mg/kg (p.o). The animals were observed continuously for first 72 h 
and then 14 days for emerging signs of behavioral changes, body weight changes and 
for mortality. 
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Occurrence of toxicity in animals were observed continuously for the first 4 to 
24 h and observed periodically for the next 14 days.  Observation includes the change 
in skin, fur, eyes and mucus membrane. Appearance of C.N.S,C.V.S and A.N.S related 
toxicity such as tremors, convulsions, sedation, steric behavior, respiratory distress, 
cardiovascular collapse, response to sensory stimuli, salivation, diarrhea, lethargy, 
sleep, coma and mortality were observed with special attention. 
Body weight was recorded periodically. At the end of the experiment all 
animals were subjected for gross necropsy and observed for pathological changes. 
 
SUB-ACUTE TOXICITY STUDY - OECD Guideline - 407. [71] 
Animals 
Healthy adult Wistar albino rat weighing between 170-200 g were used for the 
study.  The animals were housed in poly propylene cages and were kept in well 
ventilated with 100% fresh air by air handling unit (AHU). A 12 light / dark cycle 
were maintained .Room temperature was maintained between 22 + 2o C and relative 
humidity 50–65%. They were provided with food (Sai feeds, Bangalore, India) and 
water ad libitum. All the animals were acclimatized to the laboratory for 7 days prior 
to the start of the study. 
The experimental protocol was approved by The Institutional Animal Ethics 
Committee of Sathyabama University, Chennai, Tamil Nadu, India. 
 
Animal Grouping 
Animals were divided into three groups of 06 animals each consist of 3 male 
and 3 female rats. 
GROUP I : Animals received saline 5 ml/kg b.w (p.o)             
GROUP II : Animals received low dose of test drug 200 mg/kg (p.o) 
GROUP III : Animals received high dose of test drug 400 mg/kg (p.o) 
The animals were randomly divided into control group and drug treated 
groups for two different doses viz. low dose (200 mg/kg b.w) and high dose (400 
mg/kg b.w). 
The animals were administrated with the study drug once daily for 28 days. 
The animals in group I (control group) received normal saline 5 ml/kg b.w.  
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The animals in group II received low dose of Pungampoo Chooranam 200 
mg/kg b.w (p.o) and group III received high dose of Pungampoo Chooranam 400 
mg/kg b.w (p.o). 
The rats were weighed periodically and observed for signs of toxicity pertains 
to C.N.S, C.V.S, A.N.S including behavioral changes, food - water intake and 
morphological changes. At the end of 28th day, the animals were fasted for overnight 
with free access to water. On 29th day the animals were sacrificed with excess 
anesthesia. Blood samples were collected from aorta and stored in EDTA 
(ethylenediamine –tetra actate) for Hematological analysis and for serum generation 
for biochemical analysis. 
The vital organs including heart, brain, lungs, spleen, kidneys, liver, stomach, 
testes, and ovary were harvested and carefully examined for gross lesions. The organs 
were preserved in 10% formalin for histopathological assessment and interpretation. 
Hematological analysis 
Blood samples were analyzed using established procedures and automated 
Bayer Hematology analyzer. Parameters evaluated include Packed Cell Volume 
(PCV), Red Blood Cells (RBC) count, White blood cell count (WBC), Platelet Count, 
Hemoglobin (Hb), Mean cell Haemoglobin Concentration (MCHC), Mean Red Cell 
Volume (MCV), Mean Cell Hemoglobin (MCH), Mean platelet volume (MPV), 
Neutrophils, Eosinophil’s, Basophils, Lymphocytes and Monocytes.  
Biochemical analysis [72] 
Serum samples were analyzed for High Density Lipoprotein (HDL), Low 
density Lipoprotein (LDL) , Very low density Lipoprotein (VLDL) , Triglycerides 
(TGL), Total Cholesterol , Blood urea nitrogen (BUN), Creatinine, Albumin, Total 
Protein, Glucose, Uric acid, Aspartate Transaminase (AST), Alanine amino 
Transaminase (ALT) and Alkaline  Phosphatase (ALP) using Mind ray auto analyzer 
model BS 120. 
Histopathological evaluation [73] 
 Organs included of heart, brain, lungs, spleen, kidneys, liver, stomach, testes 
and ovary. Histological slides of organs were made and observed under the 
microscope.  The pathological observations of cross section of these organs were 
performed on gross and microscopic bases. Histological examinations were performed 
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on the preserved tissues with particular emphasis on those which showed gross 
pathological changes. 
Statistical analysis 
The statistical analysis was carried by one way ANOVA (GRAPH PAD 
PRISM 5 computer program). Results were expressed as mean ± standard error .A 
statistical comparison was carried out using the Dunnet’s test for the control and 
treatment group.  
Acute Toxicity Study 
Analysis Group I 
Consistency Soft 
Shape Pointed Head 
Colour Greenish brown 
Mucous Shedding Absence 
Blood Cells Absent 
Signs of Infection None Observed 
 
  Sub-Acute Toxicity Study 
Analysis Group I Group II Group III 
Consistency Soft Soft Soft 
Shape Oblong Pointed Head 
Pointed 
Head 
Colour Greenish brown Greenish brown 
Greenish 
brown 
Mucous Shedding Absence Absence Absence 
Blood Cells Absent Absent Absent 
Signs of Infection None Observed None Observed 
None 
Observed 
 
 
 
 
 
 
  
Page | 124  
 
RESULTS 
Assessment of clinical signs in rats treated with Pungampoo Chooranamon Acute 
toxicity study 
 
Parameter Group I 
Clinical Signs Parameters for the duration of 14 days Test Drug 2000mg/ Kg   
Number of animals observed 6 Female  
Lacrimation Absence 
Salivation Absence 
Animal appearance Normal 
Tonic Movement Absence 
Clonic Movement Absence 
Laxative action Very Mild 
Touch Response Normal 
Response to Sound Normal Response 
Response to Light Normal Response 
Mobility Normal Response 
Respiratory Distress Nil 
Skin Color Normal 
Stereotype behavior Absence 
Piloerection Absence 
Limb Paralysis Absence 
Posture Normal 
Open field behavior Normal 
Gait Balancing Normal 
Freezing Behaviour Absent 
Signs of Stress and Anxiety None Observed 
Muscular coordination Normal 
Muscle grip Normal 
Sedation Absence 
Social Behavior Normal 
Urine Analysis No Abnormality 
Urine Colour Yellowish 
Urine pH 7 
Urine -Glucose                         Absence 
Urine -Ketones                        Absence 
Urine- Bilirubin                         Absence 
Urine-Blood  Cells       Negative 
Urine - Pus cells Negative 
Mortality Nil 
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Quantitative data on the body weight of rats treated with Pungampoo 
Chooranam in Acute toxicity study 
Group I 
Before Treatment Weight in 
Gms 
After Treatment Weight in 
Gms 
Mean 
172.8 175.5 
Std. 
Deviation 
3.312 3.619 
Std. Error 
1.352 1.478 
 
Values are mean ± S.D (n = 6 per group). Control and treatment group were compared 
statistically using one way ANOVA followed by Dunnett’s test. 
 
Assessment of clinical signs in rats treated with Pungampoo Chooranamon Sub-
Acute toxicity study 
Parameter Group I Group II Group III 
Clinical Signs Parameters 
for the duration of 28 
days Control 
Test Drug 
200mg/ Kg    
Test Drug 
400mg/ Kg    
Number of animals 
observed 
3 Male and 3 
Female 
3 Male and 
3 Female 
3 Male and 
3 Female 
Lacrimation Absence Absence Absence 
Salivation Absence Absence Absence 
Animal appearance Normal Normal Normal 
Tonic Movement Absence Absence Absence 
Clonic Movement Absence Absence Absence 
Laxative action Absence Absence Very Mild 
Touch Response Normal Normal Normal 
Response to Sound 
Normal 
Response 
Normal 
Response 
Normal 
Response 
Response to Light 
Normal 
Response 
Normal 
Response 
Normal 
Response 
Mobility Normal Normal Normal 
Respiratory Distress Nil Nil Nil 
Skin Color Normal Normal Normal 
Stereotype behavior Absence Absence Absence 
Piloerection Absence Absence Absence 
Limb Paralysis Absence Absence Absence 
Posture Normal Normal Normal 
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Parameter Group I Group II Group III 
Open field behavior Normal Normal Normal 
Gait Balancing Normal Normal Normal 
Freezing Behaviour Absent Absent Absent 
Sings of Stress and 
Anxiety 
None 
Observed 
None 
Observed 
None 
Observed 
Muscular coordination Normal Normal Normal 
Muscle grip Normal Normal Normal 
Sedation Absence Absence Absence 
Social Behavior Normal Normal Normal 
Urine Analysis 
No 
Abnormality 
No 
Abnormality 
No 
Abnormality 
Urine Colour Yellowish 
Pale 
yellowish 
Pale 
yellowish 
Urine pH 6 7 7 
Urine -
Glucose                         Absence Absence Absence 
Urine -
Ketones                        Absence Absence Absence 
Urine- 
Bilirubin                         Absence Absence Absence 
Urine-Blood  Cells       Negative Negative Negative 
Urine - Pus cells Negative Negative Negative 
Mortality Nil Nil Nil 
 
Effect of Pungampoo Chooranam on Body weight of Rats in Sub-acute toxicity 
study 
Group I 
Before Treatment Weight 
in Gms 
After Treatment Weight in 
Gms 
Mean 
177.3 184.5 
Std. 
Deviation 
5.82 6.348 
Std. Error 
2.376 2.592 
Group II 
Before Treatment Weight 
in Gms 
After Treatment Weight in 
Gms 
Mean 
186.5 198.7 
Std. 
Deviation 
5.32 5.715 
Std. Error 
2.172 2.333 
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Group III 
 
Before Treatment 
 
After Treatment Weight in 
Gms 
Mean 
183 196.3 
Std. 
Deviation 
5.514 6.088 
Std. Error 
2.251 2.486 
 
Values are mean ± S.D (n = 6 per group of which 3 males and 3 females). Control and 
treatment groups were compared statistically using one way ANOVA followed by 
Dunnett’s test. 
 
Quantitative data on the food and water intake of rats treated with Pungampoo 
Chooranam for 28 days in Sub-acute toxicity study 
GROUP I Food intake Water intake 
Mean 17.75 29.92 
Std. Deviation 0.5693 0.9574 
Std. Error 0.2846 0.4787 
GROUP II Food intake Water intake 
Mean 17.75 29.92 
Std. Deviation 3.775 1.101 
Std. Error 1.887 0.5507 
GROUP III Food intake Water intake 
Mean 20.08 34.42 
Std. Deviation 3.957 2.267 
Std. Error 1.978 1.133 
 
Values are mean ± S.D (n = 6 per group of which 3 males and 3 females). Control and 
treatment groups were compared statistically using one way ANOVA followed by 
Dunnett’s test. 
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Effect of Pungampoo Chooranam on Haematology profile of rats in sub-acute 
toxicity study 
GROUP I 
 WBC 
count 
(×103 
µl) 
RBC 
(×10 6 µl) 
PLT 
(×10 3 
µl) 
MCV     
(fl) 
MCH    
(pg) 
MCHC 
(g/dl) 
HGB 
(g/dl) 
Mean 12.23 5.817 918.7 60.92 19.82 31.42 11.07 
Std. 
Deviation 2.719 0.9683 71.46 2.062 2.04 1.292 1.507 
Std. Error 1.11 0.3953 29.17 0.842 0.8328 0.5275 0.6152 
GROUP II 
 WBC 
count 
(×103 
µl) 
RBC 
(×10 6 µl) 
PLT 
(×10 3 
µl) 
MCV     
(fl) 
MCH    
(pg) 
MCHC 
(g/dl) 
HGB 
(g/dl) 
Mean 11.12 7.783 710 58.97 20.22 32.48 11.17 
Std. 
Deviation 1.046 1.055 279.5 3.893 3.268 1.393 1.508 
Std. Error 0.4269 0.4308 114.1 1.589 1.334 0.5689 0.6157 
GROUP 
III 
 WBC 
count 
(×103 
µl) 
RBC 
(×10 6 µl) 
PLT 
(×10 3 
µl) 
MCV     
(fl) 
MCH    
(pg) 
MCHC 
(g/dl) 
HGB 
(g/dl) 
Mean 11.73 6.15 725.2 59.7 19.3 31.15 12.57 
Std. 
Deviation 2.858 0.7064 299.3 3.3 2.467 1.924 1.94 
Std. Error 1.167 0.2884 122.2 1.347 1.007 0.7856 0.7919 
 
Values are mean ± S.D (n = 6 per group of which 3 males and 3 females). Control and 
treatment groups were compared statistically using one way ANOVA followed by 
Dunnett’s test. 
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Effect of Pungampoo Chooranam on Haematology profile of rats in sub-acute 
toxicity study. 
GROUP I 
Lymph        
(%) 
Mon            
(%) 
Neutrophils     
(X 103/mm3) Eosinophils 
(%) 
Basophils 
(%) 
MPV 
(fl) 
Mean 69.98 2.633 2.083 1.283 0.3333 6.483 
Std. 
Deviation 3.602 1.102 0.9453 0.2639 0.5164 1.003 
Std. Error 1.47 0.4499 0.3859 0.1078 0.2108 0.4094 
GROUP 
II 
Lymph        
(%) 
Mon            
(%) 
Neutrophils     
(X 103/mm3) Eosinophils 
(%) 
Basophils 
(%) 
MPV 
(fl) 
Mean 78.53 2.15 2.233 1.333 0.5 6.1 
Std. 
Deviation 7.821 0.9874 0.7394 0.2582 0.5477 1.468 
Std. Error 3.193 0.4031 0.3018 0.1054 0.2236 0.5994 
GROUP 
III 
Lymph        
(%) 
Mon            
(%) 
Neutrophils     
(X 103/mm3) Eosinophils 
(%) 
Basophils 
(%) 
MPV 
(fl) 
Mean 77.45 3.65 1.883 1.417 0.5 6.117 
Std. 
Deviation 8.302 1.093 0.736 0.2041 0.5477 1.373 
Std. Error 3.389 0.4463 0.3005 0.08333 0.2236 0.5606 
 
Values are mean ± S.D (n = 6 per group of which 3 males and 3 females). Control and 
treatment groups were compared statistically using one way ANOVA followed by 
Dunnett’s test. 
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Effect of Pungampoo Chooranam on Serum Bio-chemistry profile of rats in sub-acute toxicity study 
GROUP I 
Blood 
sugar ® 
(mg/dl) 
BUN 
(mg/dl) 
 Serum 
creatinine 
(mg/dl) 
Serum total 
cholesterol 
(mg/dl) 
Serum triglycerides 
level (mg/dl) 
Serum HDL 
cholesterol 
(mg/dl) 
Serum LDL 
cholesterol 
(mg/dl) 
Serum VLDL 
cholesterol 
(mg/dl) 
Mean 82.33 19.67 0.7167 122.7 74.5 59.17 55 14.43 
Std. Deviation 13.75 2.338 0.2927 6.088 10.41 15.88 7.849 3.189 
Std. Error 5.613 0.9545 0.1195 2.486 4.249 6.483 3.204 1.302 
GROUP II 
Blood 
sugar ® 
(mg/dl) 
BUN 
(mg/dl) 
 Serum 
creatinine 
(mg/dl) 
Serum total 
cholesterol 
(mg/dl) 
Serum triglycerides 
level (mg/dl) 
Serum HDL 
cholesterol 
(mg/dl) 
Serum LDL 
cholesterol 
(mg/dl) 
Serum VLDL 
cholesterol 
(mg/dl) 
Mean 82.5 13.33 0.5667 111 87 61 31 17.73 
Std. Deviation 12.69 2.875 0.2251 16.6 10.26 13.81 17.66 3.333 
Std. Error 5.182 1.174 0.09189 6.777 4.187 5.639 7.211 1.361 
GROUP III 
Blood 
sugar ® 
(mg/dl) 
BUN 
(mg/dl) 
 Serum 
creatinine 
(mg/dl) 
Serum total 
cholesterol 
(mg/dl) 
Serum triglycerides 
level (mg/dl) 
Serum HDL 
cholesterol 
(mg/dl) 
Serum LDL 
cholesterol 
(mg/dl) 
Serum VLDL 
cholesterol 
(mg/dl) 
Mean 79.33 17.5 0.7667 115.3 66.83 71.33 41.5 14.85 
Std. Deviation 11.59 2.074 0.2422 19.24 4.916 13.85 8.432 1.577 
Std. Error 4.731 0.8466 0.09888 7.856 2.007 5.655 3.442 0.6438 
 
Values are mean ± S.D (n = 6 per group of which 3 males and 3 females). Control and treatment groups were compared statistically using one 
way ANOVA followed by Dunnett’s test. 
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Effect of Pungampoo Chooranam on Serum Bio-chemistry profile of rats in sub- 
acute toxicity study 
 
 Values are mean ± S.D (n = 6 per group of which 3 males and 3 females). Control    
 and treatment groups were compared statistically using one way ANOVA followed    
 by Dunnett’s test. 
GROUP I 
Serum 
total 
protein 
(g/dl) 
Serum 
albumin 
(g/dl) (AST)  (IU/ml) 
(ALT) 
(IU/L) 
(ALP) 
(IU/L) 
Mean 5.483 2.75 101.3 20.5 139.2 
Std. 
Deviation 1.08 0.5648 20.53 2.881 58.25 
Std. Error 0.4408 0.2306 8.381 1.176 23.78 
GROUP II 
Serum 
total 
protein 
(g/dl) 
Serum 
albumin 
(g/dl) (AST)  (IU/ml) 
(ALT) 
(IU/L) 
(ALP) 
(IU/L) 
Mean 4.967 3.783 88.17 39.33 163.3 
Std. 
Deviation 1.172 0.7679 19.96 6.121 27.72 
Std. Error 0.4787 0.3135 8.15 2.499 11.32 
GROUP III 
Serum 
total 
protein 
(g/dl) 
Serum 
albumin 
(g/dl) (AST)  (IU/ml) 
(ALT) 
(IU/L) 
(ALP) 
(IU/L) 
Mean 5.433 2.45 109.7 24.83 154 
Std. 
Deviation 0.6713 0.6834 13.6 5.419 63.17 
Std. Error 0.2741 0.279 5.554 2.212 25.79 
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Quantitative data on absolute organ weight of rats treated with Pungampoo Chooranam for 28 days in Sub-acute toxicity study 
GROUP I 
HEART 
(gms) 
 LIVER 
(gms) 
KIDNEYS 
(gms) 
SPLEEN 
(gms) 
BRAIN   
(gms) 
LUNG    
(gms) 
STOMACH   
(gms) 
TESTES 
(gms) 
UTERUS & 
OVARY 
(gms) 
Mean 0.65 6.178 1.437 0.6 1.567 1.783 1.283 3.867 1.4 
Std. 
Deviation 0.1467 0.5603 0.2587 0.1673 0.1862 0.3189 0.3869 0.4041 0.1 
Std. Error 0.05989 0.2288 0.1056 0.06831 0.07601 0.1302 0.1579 0.2333 0.05774 
GROUP II 
HEART 
(gms) 
 LIVER 
(gms) 
KIDNEYS 
(gms) 
SPLEEN 
(gms) 
BRAIN   
(gms) 
LUNG    
(gms) 
STOMACH   
(gms) 
TESTES 
(gms) 
UTERUS & 
OVARY 
(gms) 
Mean 0.6283 6.022 1.487 0.5667 1.633 1.6 1.333 3.033 1.133 
Std. 
Deviation 0.06242 1.324 0.3024 0.1366 0.1633 0.1414 0.3011 0.3786 0.05774 
Std. Error 0.02548 0.5405 0.1235 0.05578 0.06667 0.05774 0.1229 0.2186 0.03333 
GROUP 
III 
HEART 
(gms) 
 LIVER 
(gms) 
KIDNEYS 
(gms) 
SPLEEN 
(gms) 
BRAIN   
(gms) 
LUNG    
(gms) 
STOMACH   
(gms) 
TESTES 
(gms) 
UTERUS & 
OVARY 
(gms) 
Mean 0.7967 4.902 1.458 0.7 1.633 1.833 1.5 3.033 1.4 
Std. 
Deviation 0.07174 0.3578 0.3156 0.228 0.2338 0.2805 0.395 0.4163 0.1 
Std. Error 0.02929 0.1461 0.1289 0.09309 0.09545 0.1145 0.1612 0.2404 0.05774 
 
Values are mean ± S.D (n = 6 per group of which 3 males and 3 females) for Heart, Liver, Kidney, Brain, Spleen, Lung, Stomach.   Values are 
mean ± S.D (n = 3 per group per sex ) for testes , ovary and uterus for Control and treatment groups were compared statistically using one way 
ANOVA followed by Dunnett’s test. 
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Histopathology of Brain (Female Rat) in Sub-acute toxicity Study 
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Histopathology of Heart (Female Rat) in Sub-acute toxicity Study 
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High Power Magnification 40X 
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Histopathology of Kidney (Female Rat) in Sub-acute toxicity Study 
Low Power Magnification 10X 
 
 
 
 
                         GROUP I    GROUP II             GROUP III 
 
High Power Magnification 40X 
 
 
 
 
 
                      GROUP I          GROUP II          GROUP III 
 
 
 
  
Page | 135  
 
 
Histopathology of Liver (Female Rat) in Sub-acute toxicity Study 
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Histopathology of Lung (Female Rat) in Sub-acute toxicity Study 
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High Power Magnification 40X 
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Histopathology of Spleen (Female Rat) in Sub-acute toxicity Study 
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Histopathology of Stomach (Female Rat) in Sub-acute toxicity Study 
Low Power Magnification 10X 
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Histopathology of Uterus (Female Rat) in Sub-acute toxicity Study 
Low Power Magnification 10X 
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High Power Magnification 40X 
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Histopathology of Ovary (Female Rat) in Sub-acute toxicity Study 
Low Power Magnification 10X 
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Histopathology of Brain (Male Rat) in Sub-acute toxicity Study 
Low Power Magnification 10X 
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Histopathology of Heart (Male Rat) in Sub-acute toxicity Study 
Low Power Magnification 10X 
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High Power Magnification 40X 
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Histopathology of Kidney (Male Rat) in Sub-acute toxicity Study 
Low Power Magnification 10X 
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Histopathology of Liver (Male Rat) in Sub-acute toxicity Study 
Low Power Magnification 10X 
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Histopathology of Lung (Male Rat) in Sub-acute toxicity Study 
Low Power Magnification 10X 
 
 
 
 
 
                    GROUP I            GROUP II     GROUP III 
 
 
 
  
Page | 142  
 
High Power Magnification 40X 
 
 
 
 
 
                      GROUP I         GROUP II           GROUP III 
 
Histopathology of Spleens (Male Rat) in Sub-acute toxicity Study 
Low Power Magnification 10X 
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Histopathology of Stomach (Male Rat) in Sub-acute toxicity Study 
Low Power Magnification 10X 
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Histopathology of Testes (Male Rat) in Sub-acute toxicity Study 
Low Power Magnification 10X 
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High Power Magnification 40X 
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HISTOPATHOLOGY REPORT 
BRAIN:  
Neurons are very intact and there were no signs of edema or degeneration. No 
signs of ischemia or lesion were observed in sample belongs to group I,II and III. 
LUNG:  
Perivascular region appears normal, Alveolar septa and wall appeared widen 
and normal. No signs of airway secretion and bronchial secretion. Bronchial blood 
vessels and connective tissue appears normal with no signs of pulmonary edema were 
observed in both control and treated rats. 
HEART:  
Nucleus appears prominent with regular arrangement of fibres.No evidence on 
accumulation of adipose tissue on interstitium were observed in samples belongs to 
group I, II and III. 
STOMACH:  
Mucosal epithelium appears normal with no signs of ulceration.Lumina of 
blood vessels appears normal. Appearance of glandular lumen was normal in sample 
belongs to group I, II and III. 
LIVER:  
Hepatocyte appears with dark pigment chromatin in centri lobular and 
periportal region were observed in sample belongs to group I, II and III 
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SPLEEN:  
Appearance of LF – lymphoid follicle; PALS – periarterial lymphoid sheath 
was normal with no significant signs of enlargement were observed in sample belongs 
to group I, II and III. 
KIDNEY:  
No evidence of lymphocytic infiltrate and inflammation. Epithelial lining on 
proximal convoluted tubule appears normal in sample belongs to group I,II and III. 
TESTES:  
Histo cytology of testicular tissue shows well differentiated germ cells with 
respect of spermatogonia includes spermatid and sperm were observed in sample 
belongs to group I,II and III. 
UTERUS: 
Appearance of endometrium, myometrium and uterine glands was normal. 
Arrangement of stratum basale, functionale and surface epithelium seems normal in 
samples belongs to group I, II and III. 
OVARY:  
Histopathological analysis of ovary showing normal corpus luteum (CL) and 
Primordial follicles with few mature ovarian follicles with no signs of abnormality. 
Appearance of antral follicle, primary oocyte and secondary follicles are normal in 
sample belong to group I, II and III. 
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PHARMACOLOGICAL STUDY 
IAEC: SU/CLATR/IEAC/VII/051/2016 
Animals 
Healthy adult Wistar albino male rats weighing between 220-240 g were used 
for the study.  The animals were housed in poly propylene cages and were kept in 
well ventilated with 100% fresh air by air handling unit. A 12 light / dark cycle were 
maintained .Room temperature was maintained between 22 + 2o Cand relative 
humidity 50–65%. They were provided with food (Sai feeds, Bangalore, India) and 
water ad libitum. All the animals were acclimatized to the laboratory for 7 days prior 
to the start of the study.The experimental protocol was approved by The Institutional 
Animal Ethics Committee of Sathyabama University, Chennai, Tamil Nadu, India. 
Experimental Methodology 
The animals were grouped into four groups of 6 animals each. Group I 
(Control group) -received normal saline,.Group II – Diabetic control rats administered 
with 45 mg/kg,i.p of STZ, Animals belongs to group III received 45 mg/kg,i.p of STZ 
and treated with 200mg/kg of  PungampooChooranam. Animals belongs togroup IV 
received 45 mg/kg,i.p of STZ and treated with 400mg/kg of  PungampooChooranam. 
Induction of Diabetes  
Streptozotocin (STZ), at a dose of 45 mg/kg body weight was dissolved in citrate 
buffer, injected intraperitoneally to induce diabetes. The animals will be fasted for 
16hrs before prior to STZ injection, and after the injection 5% sucrose will be 
supplemented for 24hrs in order to prevent the animals from fatal hypoglycemia. One 
week after STZ injection, blood glucose level was checked using glucometer. The 
animals with a blood glucose level of more than 300 mg/dl were considered diabetic 
and included in the study. 
Body Weight and Glucose estimation  
The fasting blood glucose was measured on 0th, 14th and 28th day by glucose 
estimation strip. Body weight of the animals was measured before start of the study 
and also at the end of the study. 
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Sample Collection  
At the end of the study, before sacrifice, the animals were fasted for overnight 
with free access to water. Animals were sacrificed with excess anesthesia. Blood 
samples were collected from retro orbital and cardiac puncture and stored in clot 
activator coated test tubes for serum biochemical analysis. Pancreas sample were 
harvested and carefully investigated for gross lesions. 
Histopathology  
A portion of pancreatic tissue was dissected out and fixed in 10% buffered neutral 
formal saline and processed. After fixation, tissues were embedded in paraffin. Fixed 
tissues were cut at 10 µm and stained with hematoxylin and eosin. The sections were 
examined under light microscope for histological changes. 
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Effect of PungampooChooranam on body weight of control and STZ induced 
experimental rats 
  Before Treatment After Treatment 
GROUP I Body Weight in gms (0th day ) 
Body Weight in gms (28th 
Day) 
Mean 225.2 260.8 
Std. Deviation 7.387 7.935 
Std. Error 3.016 3.24 
  Before Treatment After Treatment 
GROUP II Body Weight in gms (0th day ) 
Body Weight in gms(28th 
Day) 
Mean 221.5 188 
Std. Deviation 7.287 4.94 
Std. Error 2.975 2.017 
  Before Treatment After Treatment 
GROUP III Body Weight in gms (0th day ) 
Body Weight in gms(28th 
Day) 
Mean 224.3 196.5 
Std. Deviation 5.354 5.01 
Std. Error 2.186 2.045 
  Before Treatment After Treatment 
GROUP IV Body Weight in gms (0th day ) 
Body Weight in gms(28th 
Day) 
Mean 222.7 205.5 
Std. Deviation 7.685 4.68 
Std. Error 3.138 1.91 
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Effect of PungampooChooranam on oral glucose tolerance test of control and 
STZ induced experimental rats 
  Blood glucose level (mg/dl) 
GROUP I 0 Min 60 min 120 min 
Mean 77.67 142.2 124.3 
Std. Deviation 6.532 5.382 3.615 
Std. Error 2.667 2.197 1.476 
  Blood glucose level (mg/dl) 
GROUP II treated 
with 200 mg/kg of  
0 Min 60 min 120 min 
Mean 79.33 135.5 118.8 
Std. Deviation 5.502 5.089 2.714 
Std. Error 2.246 2.078 1.108 
  Blood glucose level (mg/dl) 
GROUP III 0 Min 60 min 120 min 
Mean 79.17 126 105.8 
Std. Deviation 4.355 4.427 5.231 
Std. Error 1.778 1.807 2.136 
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Effect of PungampooChooranam on fasting blood glucose level and plasma 
insulin level of control and STZ induced experimental rats 
  
Fasting Blood glucose level (mg/dl) 
  
 
 
GROUP I 0th day  14th day 28th Day Insulin (U/L) 
Mean 78.17 80.5 80.33 15.23 
Std. Deviation 4.535 4.637 5.465 0.7607 
Std. Error 1.851 1.893 2.231 0.3106 
  
Fasting Blood glucose level (mg/dl) 
  
 
 
GROUP II 0th day  14th day 28th Day Insulin (U/L) 
Mean 75.5 283.7 311 5.917 
Std. Deviation 6.473 20.48 17.7 0.4792 
Std. Error 2.643 8.361 7.225 0.1956 
 
Fasting Blood glucose level (mg/dl) 
  
 
 
GROUP III 0th day  14th day 28th Day Insulin (U/L) 
Mean 78.17 271.5 251.7 7.233 
Std. Deviation 5.193 15.6 15.02 0.6186 
Std. Error 2.12 6.371 6.13 0.2525 
  
Fasting Blood glucose level (mg/dl) 
  
 
 
GROUP IV 0th day  14th day 28th Day Insulin (U/L) 
Mean 76.83 224.7 203.3 8.15 
Std. Deviation 6.306 8.524 10.5 0.4593 
Std. Error 2.574 3.48 4.287 0.1875 
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Effect of PungampooChooranamon HbA1C, serum urea and serum creatinine 
level of control and STZ induced experimental rats 
GROUP I HbA1C (% Hb) Serum Urea (mg/dl) 
Serum Creatinine 
(mg/dl) 
Mean 6.583 24.67 0.5667 
Std. Deviation 0.96 2.16 0.1862 
Std. Error 0.3919 0.8819 0.07601 
GROUP II HbA1C (% Hb) Serum Urea (mg/dl) 
Serum Creatinine 
(mg/dl) 
Mean 12.98 70.17 1.343 
Std. Deviation 0.8954 4.622 0.2434 
Std. Error 0.3655 1.887 0.09939 
GROUP III HbA1C (% Hb) Serum Urea (mg/dl) 
Serum Creatinine 
(mg/dl) 
Mean 11.08 57.83 0.9433 
Std. Deviation 0.9988 4.309 0.1461 
Std. Error 0.4078 1.759 0.05965 
GROUP IV HbA1C (% Hb) Serum Urea (mg/dl) 
Serum Creatinine 
(mg/dl) 
Mean 8.733 43.5 0.785 
Std. Deviation 0.5125 5.128 0.1562 
Std. Error 0.2092 2.094 0.06376 
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Histopathology of Rat Pancreas (H&E) Staining 
Low Power Magnification 10 X 
             
 
              Control Group                                                      STZ Induced Group 
 
 
 
 
 
 
 
 
 
 
 
                STZ+ 200 mg/kg of                                              STZ+400 mg/kg of  
              PungampooChooranam                                PungampooChooranam 
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Histopathology of Rat Pancreas (H&E) Staining 
High Power Magnification 40 X 
 
 
           Control Group                                                   STZ Induced Group 
 
 
 
 
 
\ 
 
 
 
 
              STZ + 200 mg/kg of                                                       STZ + 400 mg/kg of 
            Pungampoo Chooranam                                                 Pungampoo Chooranam  
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PATHOLOGY REPORT 
 Sample belongs to control group rat reveals normal histology of islet of 
Langerhans. Endocrine portion of acini zone appears normal with no signs of 
degeneration. 
 Zone of fibrosis were observed with marginal loss of beta cells on islet of 
Langerhans were observed in sample belongs to group II rats. Deposition of 
collagen around inter lobular duct and vascular stroma was observed 
 Apparent change in islets density was observed. Further there is a mild 
congestion of inter lobular blood vessels were observed occasional atrophic 
conditions of islet of Langerhans were observed.  
 Almost normal density of beta cells were preserved in sample belongs to 
group IV rats with regular acini cellular zone and proper arrangement of islet 
of Langerhans were observed in sample belongs to group IV. Gradual 
restorations of pancreatic endocrine cells were observed in this group. 
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PUNGAMPOO CHOORANAM – CHLOROFORM EXTRACT 
Stationary Phase - Silica Gel 60 F254 
Mobile Phase - Toluene : Ethyl Acetate : Acetic Acid (5: 1.5: 0.25 v/v/v) 
 
 
 
 
 
 
UV 254 nm  UV 366 nm  whitelight 575 nm 
(Derivatized) 
Color Rf  value(s) Color Rf  value(s) Color Rf value(s) 
Grey 0.12 Light Blue 0.06 Grey 0.06 
Grey 0.18 Light Blue 0. 09 Pink 0.13 
Dark blue 0.27 Blue 0. 11 Yellow 0. 27 
Green 0.32 Light Blue 0.13 Blue 0.31 
Grey 0.36 Bright Blue 0.18 Pink 0.34 
Grey 0.42 Violet 0.21 Light blue 0.39 
Green 0.48 Bright Blue 0.26 Light green 0. 44 
Dark 
green  
0.49 Bright Blue 0.27 Blue 0.48 
Blue 0. 59 Violet 0.33 Pink 0.53 
Grey 0.81 Violet 0.37 Yellowish 
green 
0.58 
Grey 0.87 Blue 0.41 Violet 0. 64 
Grey 0.97 Bright Blue 0.46 Yellowish 
green 
0. 79 
  Bright Blue 0.50 Yellowish 
green 
0.86 
  Violet 0.53 Yellowish 
green 
0.90 
  Bright Blue 0.58   
  Blue 0.62   
  Dark Red 0.65   
  Dark Red 0.68   
  Bright Red 0.73   
  Pink 0.80   
  Violet 0.86   
  Violet 0.91   
  Pink 0.98   
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HPTLC Chromatogram @ 254 nm:  
 
Peak Table @ 254 nm:  
 
3D Chromatogram @ 254 nm: 
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BIO-CHEMICAL ANALYSIS OF TRIAL MEDICINE 
 
Preparation of Sodium Carbonate extract: 
Trial drug (Pungampoo Chooranam) weighing 2 gms is mixed with 5 gms 
of Sodium carbonate and taken in a 100 ml beaker and 20 ml of distilled 
water is added. The solution is boiled for 10 minutes, cooled and then filtered. 
The filtrate is called sodium carbonate extract. 
S.No EXPERIMENT OBSERVATION INFERENCE 
I TEST FOR ACID RADICALS 
1(a) Test for Sulphate 
2   ml   of   the   above   prepared 
extract is taken in a test tube. To 
this add 2ml of 4% Ammonium 
oxalate solution. 
Absence of White 
Precipitate 
Absence of 
Sulphate 
1(b) 2ml of extract is added with 2ml 
of dilute hydrochloric acid until 
the effervescence ceases off. Then 
2ml barium chloride solution is 
added. 
Absence of White 
Precipitate 
Absence of 
Sulphate 
2 Test for Chloride: 
2ml of extract is added with dilute 
nitric acid till the effervescence 
ceases. Then 2ml of silver nitrate 
solution is added. 
Absence of white 
precipitate 
Absence of 
Chloride 
3 Test for Phosphate 
2ml of the extract is treated 
with 2 ml of Ammonium 
molybdate solution and 2ml of 
concentrated nitric acid. 
 
Absence of Yellow 
precipitate 
Absence of 
Phosphate 
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 4 Test for Carbonate: 
2ml  of  the  extract  is  treated with 
2ml       of       magnesium 
sulphate solution. 
Absence of white 
precipitate 
Absence of 
Carbonate 
5 Test for Sulphide: 
1 gm of the substance is treated 
with 2ml of concentrated Hcl. 
Absence of Rotten 
egg smelling 
Absence of 
Sulphide 
6 Test for Nitrate: 
1gm of the substance is heated with 
copper turnings and concentrated 
sulphuric acid and viewed the test 
tube vertically down. 
Absence of reddish 
brown gas. 
Absence of 
Nitrate 
7.a Test for Fluoride and 
Oxalate 
2ml of the extract is added with 
2ml of dilute acetic acid and 2ml of 
calcium chloride solution and 
heated. 
Absence of white  
precipitate 
Absence of 
Fluoride and 
Oxalate 
b. 5 drops of  clear solution is added 
with 2ml of diluted sulphuric acid 
and slightly warmed to this, 1 ml 
of dilute potassium permanganate 
solution is added. 
Absence of 
Discolourisation 
Absence of 
Fluoride and 
Oxalate 
8 Test for Nitrite 
3 drops of the extract is placed on a 
filter paper. On that, 2 drops of 
Acetic Acid and 2 drops of 
Benzidine solution is placed. 
Absence of yellowish 
red colour 
Absence of 
Nitrate 
9 Test for Borate 
2 pinches of the substance is made 
into paste by using Sulphuric acid 
and Alcohol (95%) and 
introduced 
Absence of Green 
tinged flame 
Absence of 
Borate 
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II TEST FOR BASIC RADICALS 
10 Test for lead 
2 ml of the extract is added with 
2 ml of Potassium iodide solution. 
Absence of Yellow 
precipitate 
Absence of Lead 
11a Test for Copper 
 
One  pinch  of  substance  is made 
into paste with concentrated 
Hydrochloric acid in a watch glass 
and introduced into the non 
luminous part of the flame. 
Absence of Bluish 
green coloured flame. 
Absence of Copper 
b 2ml   of   the   extract   is   added 
With excess of Ammonia solution 
Absence of deep blue Absence of Copper 
12 Test for Aluminium 
To the 2 ml of extract. Sodium 
Hydroxide  solution  is added in 
drops to excess 
Absence of White 
Precipitate. 
Absence of 
Aluminium 
13a Test for Iron 
To the 2 ml of extract, 2 ml of 
Ammonium Thiocyanate 
Solution is added. 
Absence of Blood red 
colour 
Absence of Iron 
b To the 2 ml of extract, 2 ml 
Of Ammonium thiocyanate 
solution and 2 ml of concentrated 
Nitric 
Absence of Blood    
red colour 
 
 
Absence of Iron 
14 Test for Zinc 
 
To the 2 ml of extract Sodium 
Hydroxide solution is added in 
drops to excess. 
Presence of White 
Precipitate. 
Presence of Zinc 
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15 Test for Calcium 
 
2 ml of the extract is added with 2 
ml of 4% Ammonium Oxalate 
solution. 
Absence of White 
Precipitate. 
Absence of Calcium 
16 Test for Magnesium 
 
2ml  of extract,  Sodium 
Hydroxide solution is added 
Absence of White 
Precipitate. 
Absence of 
Magnesium 
17 Test for Ammonium 
 
2 ml of extract few ml of Nessler’s 
Reagent and excess of Sodium 
Hydroxide solution are added. 
Absence of Reddish 
brown precipitate 
Absence of 
Ammonium 
18 Test for Potassium 
 
A pinch of substance is treated with  
2   ml   of   Sodium   Nitrite 
solution and then treated with 2ml 
of Cobalt Nitrate in 30% glacial 
Acetic acid. 
Presence  of  Yellow 
precipitate 
Presence of 
Pottasium 
19 Test for Sodium 
 
2 pinches of the substance is made 
into paste by using Hydrochloric 
acid and introduced into the blue 
flame. 
Absence of Yellow 
colour flame 
Absence of Sodium 
20 Test for Mercury 
 
2 ml of the extract is treated with 
2 ml of Sodium Hydroxide 
Absence of yellow 
precipitate 
Absence of Mercury 
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21 Test for Arsenic 
2 ml of extract is treated with 2ml 
of silver Nitrate solution. 
Absence of Yellow 
precipitate 
Absence of Arsenic 
22 Test for Starch 
2ml of extract is treated with weak 
iodine solution 
Absence of Blue 
colour 
Absence of Starch 
23 Test of reducing Sugar 
5ml of Benedict’s qualitative 
solution is taken in a test tube and 
allowed to boil for 2 minutes and 
added 10 drops of the extract and 
again boiled for 2 minutes. The 
colour changes are noted. 
Presence of Green 
colour 
Presence of 
Reducing Sugar 
24 Test of the alkaloids 
 
2ml of the extract is treated with 
2ml of  Potassium iodide solution. 
Presence of Red 
colour 
Presence of 
Alkaloids 
25 Test of the proteins 
2ml of the extract is treated with 
2ml of  5%  NaOH, mix  well  and 
add 2 drops of copper sulphate 
solution. 
Absence of Violet 
colour 
Absence of Proteins 
 
RESULTS: 
The given sample (Pungampoo Chooranam) contains, 
        Reducing Sugar, Alkaloids, Zinc and Potassium. 
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CLINICAL PROGNOSIS 
Treatment for Madhumegam: 
The most popular non parametric statistical tool, namely, McNemar Test 
analysis has been employed to analyses the effectiveness with the help of a 
hypothesis. 
 
S. No Signs&Symptoms Before Treatment After Treatment 
n% n% 
1. Polyuria 40(100) 7(17.5)** 
2. Polyphagia 40(100) 5(12.5)** 
3. Polydipsia 40(100) 4(10)** 
4. Itching present all over 
the body 
4(10) 0(0)* 
5. Pain all over the body 34(85) 7(17.5)** 
6. Dryness of Mouth & 
Throat 
40(10) 0(0)* 
7. Constipation 8(20) 0(0)* 
8. Emaciation 4(10) 3(7.5) 
9. Skin infection 4(10) 0(0)* 
10. Disturbed Sleep 40(100) 4(10)** 
 
McNemat test, C.I: 95%,  *P<0.05; **P<0.001 
Software: spss17 version 
Number of cases: 40 
Inference:  
Since the p value is significant in signs and symptoms except emaciation. So 
there is significant reducing of signs & symptoms except emaciation among the 
patients for the treatment of Madhumegam. Hence it is concluded that the treatment 
was effective and significant. 
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Effect of Pungampoo chooranam on Fasting Blood Sugar level in Madhumegam cases 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
S. no Fasting  blood sugar level in mg  
Before Treatment After Treatment 
1. 132 110 
2. 138 120 
3. 136 122 
4. 131 119 
5. 136 94 
6. 139 124 
7. 132 121 
8. 129 97 
9. 133 109 
10. 130 106 
11. 127 103 
12. 140 132 
13. 129 98 
14. 126 98 
15. 139 105 
16. 133 111 
17. 137 113 
18. 127 95 
19. 129 119 
20. 138 114 
21. 133 120 
22. 131 109 
23. 128 94 
24. 135 108 
25. 138 122 
26. 140 130 
27. 136 121 
28. 131 105 
29. 128 108 
30. 136 114 
31. 128 106 
32. 133 117 
33. 130 102 
34. 128 97 
35. 138 119 
36. 131 98 
37. 136 112 
38. 133 123 
39. 131 113 
40. 134 119 
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Software: spss17 version 
Variables: Fasting Blood Sugar Level (mg) – before treatment, after treatment 
Number of cases: 40 
Test: Paired t test 
Confidence Interval: 95% 
Correlation coefficient (r): 0.662 
Before and after treatment mean difference ± SEM: 21.80 ± 1.28 
P Value (2 tailed): p<0.001. 
Inference:  
Since the p value is significant (p<0.001). The hypothesis is not accepted. So 
there is significant reducing of Fasting blood sugar level (mg) among the patients for 
the treatment of Madhumegam. Hence it is concluded that the treatment was effective 
and significant.  
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Effect of Pungampoo chooranam on Postprandial blood Sugar level 
in Madhumegam cases. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
S. no Postprandial blood sugar level in mg 
Before Treatment After Treatment 
1. 231 193 
2. 233 191 
3. 221 188 
4. 202 168 
5. 189 152 
6. 242 218 
7. 214 180 
8. 230 188 
9. 214 181 
10. 219 186 
11. 183 161 
12. 263 217 
13. 220 159 
14. 227 161 
15. 247 196 
16. 188 143 
17. 213 177 
18. 185 157 
19. 218 169 
20. 220 173 
21. 203 171 
22. 226 180 
23. 214 179 
24. 245 208 
25. 253 188 
26. 258 203 
27. 206 174 
28. 186 166 
29. 219 179 
30. 226 187 
31. 221 176 
32. 228 179 
33. 219 186 
34. 228 176 
35. 257 221 
36. 184 168 
37. 231 173 
38. 222 182 
39. 229 197 
40. 237 181 
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Software: spss17 version 
Variables: Postprandial Blood Sugar Level (mg) – before treatment, after treatment 
Number of cases: 40 
Test: Paired t test 
Confidence Interval: 95% 
Correlation coefficient (r): 0.823 
Before and after treatment mean difference ± SEM: 40.47 ± 1.85  
P Value (2 tailed): p<0.001. 
Inference:  
Since the p value is significant (p<0.001). The hypothesis is not accepted. So 
there is significant reducing of postprandial blood sugar level (mg) among the patients 
for the treatment of Madhumegam. Hence it is concluded that the treatment was 
effective and significant.  
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Effect of Pungampoo chooranam on HbA1C level in Madhumegam cases. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
S. no HbA1C 
Before Treatment After Treatment 
1. 7.1 6.4 
2. 7.3 6.2 
3. 7.0 6.3 
4. 6.9 6.4 
5. 6.6 5.2 
6. 8.0 7.9 
7. 7.3 6.5 
8. 7.2 6.4 
9. 7.3 6.3 
10. 6.9 6.1 
11. 6.7 5.8 
12. 8.0 7.8 
13. 7.8 6.5 
14. 7.1 6.4 
15. 7.8 6.3 
16. 6.7 5.7 
17. 7.0 6.5 
18. 6.8 5.7 
19. 7.3 6.5 
20. 7.4 6.8 
21. 6.8 6.4 
22. 7.0 6.7 
23. 8.0 7.9 
24. 7.8 7.5 
25. 7.2 7.0 
26. 8.0 7.6 
27. 6.8 6.3 
28. 6.7 5.8 
29. 7.3 6.5 
30. 7.4 6.8 
31. 7.6 7.3 
32. 7.5 7.1 
33. 6.8 6.1 
34. 7.9 7.6 
35. 8.0 7.8 
36. 7.1 5.9 
37. 7.6 6.9 
38. 8.0 7.3 
39. 7.0 6.4 
40. 6.9 6.6 
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Software: spss17 version 
Variables: HbA1C Level – before treatment, after treatment 
Number of cases: 40 
Test: Paired t test 
Confidence Interval: 95% 
Correlation coefficient (r): 0.864 
Before and after treatment mean difference ± SEM: 0.66 ± 0.06 
P Value (2 tailed): p<0.001. 
Inference:  
Since the p value is significant (p<0.001). The hypothesis is not accepted. So 
there is significant reducing of HbA1C level among the patients for the treatment of 
Madhumegam. Hence it is concluded that the treatment was effective and significant.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Page | 172  
 
CONSENT FORM 
I certify that I have disclosed all the details about the study in the terms readily 
understood by the patient. 
 
DATE: SIGNATURE 
 
NAME 
 
CONSENT BY THE PATIENT 
I have been informed to my satisfaction by the attending physician the purpose 
of the clinical trial and the nature of the drug treatment and follow up including the 
lab investigations to be performed to monitor and safeguard my body functions. 
I am aware of my right to opt out of the trial at any time during the course of 
the trial without having to give reasons for doing so. 
I am exercising my free power of choice, and hereby give my consent to be 
included as a subject in the clinical trial of PUNGAMPOO CHOORANAM for the 
treatment of MADHUMEGAM. 
 
 
 
DATE: SIGNATURE 
 
NAME 
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nehahëæ‹ x¥òjš got« 
 
ÂU-------------- M»a eh‹ ---- taJ-------------------- 
 
------------------------------------------------------------ 
 
---------------------  v‹ Ra ãidÎl‹ vGÂ¡bfhL¡F« x¥òjš got«. 
 
 eh‹ kJnkf« (ÚçêÎ) v‹D« nehahš ghÂ¡fg£L br‹id muR Á¤j  kU¤Jt¡ fšÿçæš 
( Ïl« : m¿P®m©zh kU¤Jtkid,mU«gh¡f«, br‹id-106) el¤j¥gL« Á¤j kU¤Jt 
MuhŒ¢Á _y« Á»¢ir bgw v‹ KG r«kj¤ijÍ« bjçé¤J¡bfhŸ»nw‹. 
Ïªj MuhŒ¢Áæ‹ neh¡f«, kU¤Jt« brŒÍ« Kiwbjhl® f©fhâ¥ò k‰W« v‹ 
clšey‹ F¿¤j kU¤Jt gçnrhjidfis g‰¿ éçthd és¡f« vd¡F kU¤Jt« brŒÍ« kU¤Jt® _y« 
bjëÎgL¤j¥g£LŸsJ. Ïªj MuhŒ¢Áæš g§FbfhŸS« v‹ r«kj¤Â‰¡F ahUila ã®gªjK« 
fhuzäšiy v‹gij bjçé¤J¡bfhŸ»nw‹. 
 
                                                                                                        Ï¥go¡F, 
 
bga®: 
Kftç: 
 ehŸ: 
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CASE SHEET PROFORMA 
GOVERNMENT SIDDHA MEDICAL COLLEGE 
POST GRADUATE DEPARTMENT – MARUTHUVAM BRANCH 
CHENNAI – 600 106. 
 
CASE SHEET PROFORMA FOR MADHUMEGAM 
(NON INSULIN DEPENDENT DIABETES MELLITUS – NIDDM) 
 
OP No / IP No  :    Nationality : Indian 
 
Ward No  :    Religion :  
 
Bed No  :    D.O.A  : 
 
Name  
(In Block Letters) :    D.O.D  : 
 
Age   :    No of Days 
       Treated : 
Sex   :        Male/ Female    
 
Occupation  :    Diagnosis : 
 
Income/Month :    Result  : 
 
Permanent Address : 
 
 
Temporary Address :       Govt. Siddha Medical College, 
         Chennai – 600 106. 
 
1. Complaint and duration  : 
 
2. History of present illness  : 
 
3. History of previous illness  : 
 
4. Personal history 
 
 Marital History  : 
 Occupation   : 
 Environment   : 
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 Social History   : 
 Habits    : 
5. Family history   : 
 
SIDDHA ASPECT 
GENERAL CONDITION ON ADMISSION 
1. NILAM: 5 
1. Kurinji 
2. Mullai 
3. Marutham 
4. Neithal 
5. Paalai 
 
2. PARUVA KAALAM: 6 
1. Kaar Kaalam   : (Aavani, Purattasi) 
2. Koothir Kaalam : (Ayppasi, Karthigai) 
3. Munpani Kaalam : (Maarkazhi, Thai) 
4. Pinpani Kaalam : (Maasi, Panguni) 
5. Elavenil Kaalam : (Chittirai, Vaikasi) 
6. Mudhuvenil Kaalam : (Aani, Aadi)  
3. UDAL: 4 
1. Vali Udal 
2. Azhal Udal 
3. Iya Udal 
4. Kalappu Udal 
4. KANMENTHIRIYANGAL: 5 
1. Vaai 
2. Kaal 
3. Kai 
4. Eruvai 
5. Karuvai 
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5. PORI / PULANGAL: 5 
1. Mei - Ooru 
2. Vaai - Suvai 
3. Kann - Oli 
4. Mookku - Nattram 
5. Sevi – Osai 
 
6. GUNAM: 3 
1. Sathuva Gunam 
2. Rajo Gunam  
3. Thamo Gunam 
 
7. UDAL KATTUGAL: 7 
1. Saaram 
2. Senneer 
3. Oon 
4. Kozhuppu 
5. Enbu 
6. Moolai 
7. Sukkilam / Suronitham 
 
8. MALAM: 3 
1. Malam 
2. Moothiram 
3. Viyarvai 
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9. MUKKUTRANGAL 
 VALI 
1. Piraanan 
2. Abaanan 
3. Uthaanan 
4. Viyaanan 
5. Samaanan 
6. Naagan 
7. Koorman 
8. Kirukaran 
9. Devathathan 
10. Dhananjeyan 
  AZHAL 
1. Anala Pitham 
2. Ranjaga Pitham 
3. Aalosaga Pitham 
4. Praasaga Pitham 
5. Saathaga Pitham 
  IYAM 
1. Avalambakam 
2. Kilethagam 
3. Pothagam 
4. Tharpagam 
5. Santhigam 
 
10. ENVAGAI THERVU 
1.Naadi 
2.Sparisam 
3.Naa 
4.Niram 
5.Mozhi 
6.Vizhi  
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7.Malam: 
I. Niram 
II. Irugal 
III. Ilagal 
8. Moothiram: 
I. Neerkuri: 
i. Niram 
ii. Edai 
iii. Manam 
iv. Nurai 
v. Enjal 
II. Neikuri: 
    
MODERN METHODS: 
General Examination: 
 Consciousness and Intelligence 
 Voice and Speech 
 General appearance 
 Height and Weight 
 Anaemia 
 Cyanosis 
 JVP 
 Jaundice 
 Clubbing 
 Ascites 
 Oedema 
 Lymphadenopathy 
 Temperature 
 Respiration 
 Pulse 
 Blood Pressure 
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INVESTIGATION 
A) BLOOD INVESTIGATIONS: 
  
 
BLOOD INVESTIGATIONS 
 
BEFORE 
TREATMENT 
 
AFTER 
TREATMENT 
Blood 
glucose  
(mg/dl) 
F 
  
PP 
  
Renal 
Function 
Test 
Blood Urea 
  
Serum 
creatinine 
  
Lipid Profile Serum 
Cholestrol 
  
 
B)  URINE INVESTIGATIONS: 
 
URINE 
INVESTIGATIONS 
 
BEFORE 
TREATMENT 
 
AFTER 
TREATMENT 
Urine Sugar (F) 
  
Urine Sugar (PP) 
  
 
C) SPECIFIC INVESTIGATIONS: 
 
 
HbA1C 
 
BEFORE 
TREATMENT 
 
AFTER 
TREATMENT 
  
 
 
D) BODYMASS INDEX (BMI) 
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SIGNS AND SYMPTOMS: 
 
S.No 
 
CLINICAL 
FEATURES 
 
BEFORE 
 TREATMENT 
 
DURATION TREATMENT 
 
AFTER 
TREATMENT 
14th 
Day 
21st 
Day 
28th 
Day 
35th 
Day 
42nd 
Day 
49th 
Day 
1 Polyuria         
2 Polyphagia         
3 Polydipsia         
4 Itching All Over The 
Body 
        
5 Dryness Of The Mouth 
And Throat 
        
6 Constipation         
7 Disturbed Sleep         
8 Pain All Over The 
Body 
        
9 Skin Infection         
10 Emaciation         
11 Glycosuria         
Others specify, if any: 
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    DIAGNOSIS 
    MADHUMEGAM  (TYPE II DIABETES MELLITUS) 
Trial Drug  : PUNGAMPOO CHOORANAM 
 Dose   : 2 Gram 
Anubanam  : WARM WATER 
 Duration of Treatment : 48 days  
 
DATE WEEKLY REPORT MEDICINE 
   
 
ADVICE: 
 
Medical Officer:       H.O.D/Guide 
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DISCHARGE SHEET 
 
GOVERNMENT SIDDHA MEDICAL COLLEGE,  
POST GRADUATE DEPARTMENT 
MARUTHUVAM BRANCH, CHENNAI – 600 106. 
 
Proforma for Madhumegam 
 
IP NO  :     Date of Admission  : 
Name  :     Date of Discharge : 
Age / Sex :     No of days Treatment : 
Occupation :     Diagnosis  : 
Income:      Result   : 
Nationality :      
Religion : 
Patient condition on admission             On discharge  
Complaints and duration 
Pulse 
Weight 
Blood Pressure 
Blood Sugar 
Urea 
Serum Cholesterol 
Urine Sugar 
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